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” […] according to the principles of quantum physics, which is an accurate description of 
nature, a particle has neither a definite position nor a definite velocity unless and until those 
quantities are measured by an observer. It is therefore not correct to say that a measurement 
gives a certain result because the quantity being measured had that value at the time of the 
measurement. In fact, in some cases individual objects don’t even have an independent 
existence but rather exists only as part of many.” 
 
                                              Stephen Hawking & Leonard Mlodinow, The Great Design 
 
 






Liver failure is undeniably accompanied by distortions of the coagulation system. The 
modern theory of coagulation in patients with compensated liver disease (acute or chronic) 
states that the coagulation system is in a rebalanced state, also displaying prothrombotic 
tendencies particularly towards the end stages. Conventional coagulation tests are proved 
inappropriate in the evaluation of bleeding or thrombotic risks in these patients. Viscoelastic 
tests, such as thromboelastometry, are used clinically as point-of-care testing to determine the 
balance of coagulation and have proven particularly effective in the treatment of critical 
situations with bleeding difficult to control. Also, there have been reports that viscoelastic 
testing might be used for prognosis purposes in liver cirrhosis. A thromboelastometric 
characterization of an unselected population with an indication for liver transplantation was 
assumed to be useful. Additionally, a clarification of blood coagulation abnormalities in 
conjunction with the liver dysfunction following massive liver resections was needed. 
 
The aim of studies 1 and 2 was to characterize coagulation status in patients with liver 
conditions using thromboelastometry. In study 1 we included patients with stable chronic 
liver disease with an indication for liver transplantation.  Aside from a viscoelastic 
description, the primary aim of study 1 was to assess thromboelastometry usefulness in 
assessing the prognosis in these patients and eventually be used to improve the existing 
scoring systems. In general, the patients were normo- and hypocoagulable with no significant 
signs of hypercoagulability expressed through thromboelastometry. No relation could be 
found between thromboelastometry and the Child-Pugh and MELD scores. The conclusion of 
study 1 was that we could not find any use for thromboelastometry in evaluating the gravity 
of the stable chronic liver disease with an indication for liver transplantation. 
 
In study 2 we included patients who underwent hemihepatectomies and extended 
hemihepatectomies. Using thromboelastometry we found that postoperatively the coagulation 
system was rebalanced apparently in the same manner as in chronic liver disease and that the 
bleeding risk signalled by PT-INR was groundless.  We also found that the postoperative 
trends of plasma fibrinogen concentration were related to the size of resection. 
 
The findings in study 2 made us hypothesize that a deficiency in synthesis due to the loss of 
liver mass may be the factor which affects the plasma fibrinogen concentrations 
postoperatively. To explore this hypothesis, we needed to quantitatively assess the de novo 
synthesis of fibrinogen (and albumin) in these patients. To this end, in study 3, we adjusted 
the isotope tracer flooding dose technique to enable repetitive measurements in longitudinal 
studies.   
 
The technique described in study 3 was then used in study 4 to determine the postoperative 
synthesis rates of fibrinogen and albumin in patients undergoing hemihepatectomies and 
pancreatectomies (as controls). An extraordinary capacity of the liver to increase fibrinogen 
synthesis on postoperative day one was discovered. In this study, we found that the loss of 
liver mass through elective hemihepatectomies did not incapacitate a sharp increase in the 
synthesis rates of fibrinogen compared to pancreatectomies. Plasma fibrinogen concentrations 
may therefore reflect the dynamic changes in synthesis related to fibrinogen utilization. The 
postoperative synthesis course maintained effective fibrinogen levels for balanced 
coagulation. Albumin synthesis rates confirmed good posthepatectomy synthetic function in 
the remnant liver tissue and eventually in the regenerated liver tissue.     
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1.1 NORMAL HAEMOSTASIS 
1.1.1 Primary haemostasis 
The term primary haemostasis refers to the formation of the platelet thrombus. A normal 
primary haemostasis means also an impediment of cloth formation when it is not necessary. 
The normal endothelium has a protective role against thrombo-genesis. Three biochemical 
mechanisms controlled by the endothelium are responsible for the prevention of platelet 
activation: nitric oxide, prostacyclin and the endothelial ecto-adenosine diphosphatase (ecto-
ADPase/CD 39) pathways [1].  
In case of endothelium damage, locally generated vasoactive agents determine 
vasoconstriction which restrict the bleeding [2] and primary haemostasis begin with the 
platelet adhesion to the sub-endothelium and further, through the platelet’s aggregation in 
overlapping layers, to the formation of the platelet plug. 
Platelets are essential for primary haemostasis, but this complex process also involves 
adhesive substrates, receptors on the platelets surface (integrins and non-integrins) and 
binding proteins like fibrinogen. 
1.1.1.1 Platelets adhesion and activation 
When the endothelium is injured, molecules such as collagen, von Willebrandt factor (vWF), 
laminin, fibronectin, and trombospondin are exposed to the bloodstream [3]. These are 
ligands for the platelet’s membrane receptors and mediate platelets adhesion to the sub-
endothelium. Their relationship with the platelets depends on the blood flow dynamics [3]. In 
rapid flow conditions (arteries) platelets adhesion is mediated by the vWF [4]. At low flows 
(veins) direct binding to collagen, laminin, fibronectin prevails [3]. 
vWF is synthetized by endothelium and megakaryocytes and exists immobilised at sub-
endothelial level as well as in soluble form in plasma [4]. vWF can also be expressed on the 
platelet surface [5]. Normal vWF has a high affinity to specific platelets receptors and to 
collagen [3].   
The platelet adhesion is initiated by the interaction between the platelet membrane receptor 
glycoprotein Ib (GP Ib) (a non-integrin which coexist in a complex with GP V and IX) and 
the sub-endotehelial vWF [4]. GPIb-vWF bindings will decelerate platelets carried by the 
blood flow [4, 6]. Thus, the platelets are seized in a “rolling adhesion” which eventually 
allows establishment of more stable bonds between platelet receptor GP IIb/IIIa (integrin 
αIIbβ3) and the sub-endothelial vWF [4, 6]. P-selectin expressed by endothelial cells, as well 
released by activated platelets, facilitate the adhesion process [1, 4]. 
A stable adhesion is assured by a direct firm fastening to collagen completed through the 
platelet surface receptors GP Ia/IIa (integrin α2β1) and GP VI (a non-integrin) [3].  
The binding of vWF on GP Ib , as well as other interaction between different platelet 
receptors and their agonists, will determine the platelet activation [3, 7, 8] which will 
generate platelets degranulation, cytoskeletal modifications with subsequent shape changes of 
the platelets and finally the clot retraction [9, 10].  
During platelet degranulation, several different mediators are released, e.g. arachidonic acid 
which attracts other circulating platelets to the site of injury, or important agonists such as 
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adenosine diphosphate (ADP), thrombin, epinephrine, and thromboxane A2 (TXA2). They 
play a critical role in amplifying and sustaining the subsequent aggregation by interacting 
with receptors expressed on the platelets surface.  
1.1.1.2 Platelets aggregation. The fibrinogen role in stabilizing the platelet thrombus. 
The platelet aggregation is dependent on the interaction between platelet receptors GP Ib, GP 
IIb/IIIa and vWF and fibrinogen in a complex manner depending on blood flow share rates 
[4, 5, 8]. Although GPIb-vWF binding is required for both low and high flows [8], GP 
IIb/IIIa is the main receptor for platelets aggregation at high velocities [3]. 
While platelet activation takes place, GP IIb/IIIa is expressed, and undergoes a 
conformational change that increases its affinity for fibrinogen and the vWF [10, 11]. GP 
IIb/IIIa binds enduringly the soluble fibrinogen which molecular dimeric structure allows 
adjacent activated platelets to cross-link to underlying ones [10]. vWF competes with 
fibrinogen on GP IIb/IIIa, especially at elevated levels of platelets layers, allowing the initial 
contact between platelets [5, 10].  On mice vWF alone is not sufficient to ensure the stability 
of the platelet plug and fibrinogen is absolutely necessary in maintaining a stable platelet 
thrombus [10, 12].  
Thrombin, which is rapidity generated around activated platelets, is a potent activator of the 
platelets and promotor of platelet aggregation [10].  
1.1.1.3 Connection with the secondary haemostasis  
The processes described by the cell-based model of haemostasis occur on the surface of the 
activated platelets. 
The platelets contain pre-mRNA for tissue factor and in conjunction with platelet activation 
the synthesis of the bioactive tissue-factor is triggered. Once synthetized, the tissue factor will 
be expressed on the surface and will initiate the secondary haemostasis [13]. Activated 
platelets also release factor V, which is partially activated at the same time [14].  
In the amplification stage of the coagulation process, the receptor GP Ib/IX on the surface of 
activated platelet binds thrombin which activate fVIII and fXI (Figure 1) [15, 16]. Platelets 
express as well high-affinity binding sites for fIXa, fXa, and fXI [16]. 
 
© Georg Thieme Verlag KG 
 
Figure 1. Activation of factors VIII and XI by thrombin on the platelet surface (Reproduced 
from [16] with permission of the publisher). 
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Negatively charged phospholipids are exposed by the platelets as well and play an important 
catalytic and stabilizing role in the fibrin formation [9]. 
1.1.2 Secondary haemostasis 
Secondary haemostasis refers to the process of fibrin formation.  Over time secondary 
coagulation theory has gone through several modifications according to the evolution of the 
understanding of the coagulation mechanisms. 
In the 1930s the model of coagulation was very simple and regarded exclusively the 
activation of prothrombin under the action of thromboplastin and calcium and thus converting 
itself in thrombin which determined the fibrin formation [17]. The design of the coagulation 
test known as the prothrombin test (PT) is based on this simple model [17].  
The model called “coagulation cascade” was presented in 1964 [18, 19]. The cascade model 
proposes a sequential proteolytic activation of proenzymes into enzymes (i.e. coagulation 
factors as serine proteases), with the two pathways intrinsic and extrinsic, which ultimately 
results in the generation of thrombin that causes fibrinogen to be converted to insoluble fibrin 
[18, 19].  
A significant drawback of the cascade model was that the coagulation tests PT (which reflects 
the extrinsic pathway) and aPTT (which explores the intrinsic pathway) do not correlate with 
the risk of bleeding in all clinical situations. Different punctual deficiencies of various 
coagulation factors involved in the extrinsic pathway do not have the same risk of bleeding. 
Thus haemophilia (deficiencies in factor VIII (fVIII) or IX (fIX) have an increased risk of 
bleeding, while fXII or XI deficiencies have a significantly lower risk or not at all [17]. 
Furthermore, the cascade model cannot explain how haemophilia cannot be compensated by 
an extrinsic pathway that functions normally [16].  The in vivo activation of the intrinsic 
pathway was also questionable because deficiency of fXII, high molecular weight kininogen 
(HMK) or pre-kallikrein (PK) does not result in bleeding diathesis [16].  
Other major deficiencies of this model were that the natural anticoagulation pathways were 
not included, and the platelets remained only a part of the primary haemostasis without 
making a connection with the secondary haemostasis.  
1.1.2.1 A Cell-Based Model of haemostasis 
The new model was published in 2011 and named "A cell-based Model of Haemostasis". It 
was the result of preliminary studies that brought new knowledge about how platelets and 
clotting factors interact [16]. 
It was demonstrated for example that activated platelets external surface is a place for 
activation of fXI [15], accordingly fXII, HMK and PK might not be mandatory for 
haemostasis [16]. 
Important findings such as that the complex tissue factor (TF) - fVIIa can activate factor IX 
[20] was key information in understanding the interconnexion between the extrinsic and 
intrinsic pathways. 
The cell-based model explains that haemostasis occurs on the cell surface and involves three 
successive steps (or stages) (Figure 2 on p.4)) [16]:  
Stage 1: Initiation  
Stage 2: Amplification  




© Georg Thieme Verlag KG 
 
Figure 2. A cell-based model of coagulation (Reproduced from [16] with permission of the 
publisher) 
 
Initiation of coagulation on TF-bearing cells 
It has been demonstrated that TF is highly expressed by sub-endothelial pericytes in small 
vessels, and by adventitial cells around larger vessels under normal conditions. As long it 
remains sub-endothelial these TF-bearing cells do not trigger coagulation [21, 22]. 
An endothelial defect will allow TF-bearing to contact plasma and the TF will bind and 
activate fVII (fVIIa) [23]. The complex TF- fVIIa will then activate factor X (fXa) [23]. 
Activated platelets release partially activated factor V which will form with fXa complexes 
called prothrombinase complexes which will convert small amounts of prothrombin into 
thrombin [16]. 
The small amounts of thrombin are insufficient to promote fibrinogen polymerization at a 
large scale. It will act instead as a pro-coagulant signal for the next stage - amplification [16]. 
The next two stages take place on the surface and near the platelets trapped in the platelet 
plug. 
Amplification 
The small amounts of thrombin will determine maximal platelet activation [16]. 
Consecutively larger quantities of partially activated factor V will be released which will be 
completely activated by thrombin and fXa [16, 24]. 
Thrombin activates fVIII after releasing it from complexes von Willlebrand factor-fVIII 
which are already fasten to the activated platelets on specific receptors [16].  




In this phase fXIa will activate factor IX into fIXa which binds to fVIIIa on the platelet 
surface resulting complexes (previously called “intrinsic tenase”) [16]. 
In the presence of the activated fIXa-fVIIIa complexes, factor X is activated to fXa which 
will associate fVa and form complexes (previously called “prothrombinase”) that will 
determine an explosive thrombin generation [16].  
Notes 
Activation of fXI on the surface of the platelets in the amplification step explains why fXII is 
not required for normal haemostasis in vivo [17]. 
It is highlighted by the authors of the cell-based model that even if the haemostatic process is 
described occurring in distinct and successive steps, these stages are ongoing overlapping 
processes [16, 17].  
1.1.2.2 Fibrin network formation 
Thrombin will determine fibrinogen cleavage into soluble fibrin monomers which will 
polymerize into soluble fibrin complexes. The process is described in the section fibrin 
formation (see section 1.2.3 on p.8) 
1.1.2.3 The natural anticoagulation 
The human organism is equipped with anticoagulation mechanisms that localize the 
formation of clots to the appropriate sites and surfaces [16]. Natural occurring inhibitors of 
coagulation regulate thrombin through direct inhibition or by limitation of thrombin 
generation.  
Protease Inhibitors 
Antithrombin (AT) is synthetized by the liver and is a protease inhibitor of thrombin, fXa and 
other activated coagulation factors (p 355 in [26]).  
Tissue factor pathway inhibitor (TFPI) is a protease inhibitor produced by the endothelium 
and other cells such as megakaryocytes which restrain the coagulation process by inhibition 
of fXa through TFPI-fXa complexes which bind and inactivate TF-fVIIa [27].  
AT and TFPI will instantly inhibit the fXa if it leaves the cell surface on which it is formed 
and thus suppress the propagation of coagulation [16]. On the cells surface fXa seems to be 
relatively protected from the AT and TFPI [17, 28]. 
Activated Protein C- Protein S  
Proteins C and S are synthesized in the liver and are vitamin K–dependent factors. 
Protein C from plasma is attached by the endothelial protein C receptor (EPCR) and as a 
consequence its activity increase [29].  
Thrombomodulin (TM), which is a cell surface receptor for thrombin, will bind thrombin 
which is produced at the site of injury. While thrombin attached to TM, it loses the effect on 
fibrinogen [16]. The complex TM-thrombin has the function to activate the protein C which 
is attached via EPRC on the endothelium. In the next step, protein S form a complex with the 
activated protein C (APC) increasing the activity of the already activated protein C [30, 31]. 
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APC does not act in the fluid phase as usual anticoagulants do [17].  Its antithrombotic 
activity is limited to the endothelial surfaces [17]. 
The APC-Protein S complex inactivates fVa and fVIIIa on the endothelial surface disabling 
thrombin production [30]. 
AT, PC and PS deficiencies determine a pro-thrombotic tendency as a result of excessive 
thrombin generation [32-34]. Total TFPI deficiency does not exist in humans and partial 
deficiency is associated with a weak pro-thrombotic status [27]. 
1.1.3 Fibrinolysis 
Fibrinolysis is initiated as soon as the first fibrin polymers are born and will carry on as long 
as these filaments exist.  
The enzyme which is responsible for fibrinolysis is plasmin. Plasmin is the result of 
activation of plasminogen, its zymogen, under the action of tissue plasminogen activator 
(tPA) or, in special circumstances of urokinase-type plasminogen activator (uPA). Fibrin 
polymers attaches plasminogen and tPA on binding sites exposed after fibrinogen cleavage 
[17].  
Under normal circumstances, fine-tuning mechanisms are triggered to maintain the balance of 
fibrinolysis. Plasminogen activator inhibitor 1 (PAI-1), a serine protease inhibitor which also 
fastens to forming fibrin network, is the main inhibitor of the fibrinolytic system [36]. Hence, 
tPA is blocked by PAI-1 by forming inactive tPA -PAI-1 complexes [37]. The rate of PAI-1 
inhibition on tPA is related to its plasma concentration [35].  
As well other proteins are involved in fibrinolysis inhibition by preventing the plasmin 
action. Thrombin activatable fibrinolysis inhibitor (TAFI) protects the clot from lysis by 
removing plasminogen binding sites from fibrin, α-antiplasmin (α AP) inactivates the plasmin 
by forming complexes plasmin-antiplasmin (PAP), α2 macroglobulin (α2 MG) inactivates 
plasmin as well. 
The fibrinolysis factors are produced in the liver and endothelium in different proportions. 
Plasminogen is synthesized exclusively by hepatocytes. PAI-1 is produced by the liver but 
also by endothelium and other tissues as well [17]. TAFI, α AP and most of α2 MG are 
synthesized in the liver.  
tPA is synthesized entirely by the endothelium under stimuli such as thrombin, ischemia or 
hypoxia while uPA is produced in different tissues but not in the hepatocytes [17]. Liver 
intervenes on tPA by clearing it from plasma, with a half time for active tPA of 2-3 min and 
for tPA-PAI-1 complexes of 5-6 min [17].  
Fibrinolysis generates fibrin degradation products (FDPs) and D-dimers which are markers 
for fibrinolysis. These markers have high sensitivity but low specificity for venous thrombo-
embolism (VTE) [38-40], and thus have less reliable positive predictive value [41]. However, 
because of high sensitivity, a negative D-Dimer test can exclude thrombotic events [40]. 
Plasmin also has degrading action on fibrinogen resulting in fibrinogen degradation products 
which are similar but not identical to fibrin degradation products [42]. D-dimers are not 
markers of fibrinogenolysis (p.13 in [35]). 
Fibrinogen degradation product fragment D have the potential to stimulate the fibrinogen 
synthesis by releasing the “hepatocyte stimulating factor” (i.e. IL-6) [43] in macrophage cell 





1.2.1 Fibrinogen structure 
Fibrinogen is a glycoprotein with a molecular mass of 340 kDa. Fibrinogen structure consists 
of two identical chains of polypeptides. Each chain is made of three polypeptides namely Aα, 
Bβ and ϒ which are helically intertwined around each other and bind together by disulfide 
bonds [45, 46]. In the middle of the molecule, between the two symmetrical (Aα, Bβ, ϒ) 
chains, there is a smaller globular central region called E region which consists of 
fibrinopeptides A and B situated at the N-terminal of the peptide-chains Aα and Bβ 
respectively. Each end of the fibrinogen molecule presents a globular region called D region 
which contains the β and ϒ peptide nodules [46]. 
1.2.2 Fibrinogen metabolism (distribution, synthesis, catabolism) 
1.2.2.1 Fibrinogen distribution in the human body 
Fibrinogen's normal plasma concentration is 1.5-4.0 g/L (measured with the Clauss method) 
[42].  
Plasma fibrinogen concentration is altered under pathological conditions. It rises as a result of 
an acute inflammatory process [47] or decline as in liver insufficiency [48, 49].  
Although most of the fibrinogen (72%) is located in plasma [50, 51], other body 
compartments like the lymph nodes and the interstitial fluid can also contain fibrinogen [42]. 
The platelet alpha granules contain fibrinogen though it is not certain if it is structurally and 
functionally identical to the plasma fibrinogen [42].  
In studies with radio-isotopically labelled fibrinogen transcapillary escape rate (TER) is 
estimated to be around 60 % of the plasma pool per day [50, 51]. 
1.2.2.2 Fibrinogen synthesis in humans 
In humans, fibrinogen is mainly (at least 98%) synthesized by the liver, both under normal 
circumstances and during the acute phase reaction [52]. Extra-hepatic tissues such as 
epithelial cells synthesize fibrinogen [52, 53] but it is unlikely that the extra-hepatic synthesis 
contributes significantly to the plasma concentration [52]. 
Fibrinogen synthesis rates  
The normal rate of synthesis for fibrinogen in adults is about 1.7-5.0 g fibrinogen per day, 
and the normal half time is 3-5 days [42, 51]. 
Fibrinogen synthesis is quantified, only in a few studies which used isotopic tracer 
techniques. In healthy young non-smokers subjects’ studies using the flooding dose technique 
reported mean fractional synthesis rate (FSR) of 14%/day and absolute synthesis rate (ASR) 
of 22 mg/kg/day [54, 55].  The synthesis rates in healthy volunteers depends on factors such 
as age, feeding or smoking [54, 55]. In elderly fibrinogen synthesis is reported to be reduced 
[55], while smoking and feeding increase the fibrinogen production [54, 55]. 
Inflammation and fibrinogen synthesis  
Fibrinogen is an acute-phase protein and systemic inflammation is associated with a 
significant increase in its plasma concentration [47]. Interleukin 6 (IL-6) is the major inducer 
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of the acute-phase response in humans [43, 56], as demonstrated on human hepatocyte 
cultures where IL-6 determine increases of fibrinogen synthesis [43, 56]. Interleukin 1β (IL-
1β) inhibits the stimulating action of IL-6 on the synthesis of acute-phase proteins, including 
fibrinogen [43, 56]. TNF-α which is one of the first cytokines released after trauma has no 
stimulating effect on hepatocytes synthesis [43]. 
1.2.2.3 Fibrinogen catabolism  
Some effort has been made in elucidating the fibrinogen catabolic pathways, still, these 
remain broadly unknown [42]. The calculated fractional catabolic rate, using iodine-labelled 
fibrinogen as a tracer, is around 24% of the plasma pool/day [50].  
The catabolic pathways of fibrinogen are not completely understood. Contrary to what might 
be expected, fibrin formation-fibrinolysis seems not to be the main mechanism of fibrinogen 
catabolism under normal physiological circumstances [42, 50]. One study suggests that the 
thrombin pathway could be responsible for a maximum of 3% of fibrinogen catabolism under 
normal conditions [57]. However, in prothrombotic conditions or perioperatively the pathway 
of fibrin formation can gain significant proportion [57, 58]. 
Other proposed mechanisms such as degradation by plasmin have not been demonstrated to 
support substantially the fibrinogen catabolism [42, 44, 50].   
1.2.3 Fibrin formation  
During secondary haemostasis, fibrinogen plays a fundamental role in the construction of the 
clot. The process of fibrin clot formation comprises three phases: 
1. Conversion of fibrinogen to soluble fibrin monomers under the action of thrombin. 
Thrombin binds to fibrinogen and removes fibrinopeptids A (at fast rate) and B (at slower 
rate) in the central E region which convert the fibrinogen molecule in a fibrin monomer [59]. 
Thus, polymerization sites are exposed, and the fibrin monomers will spontaneously form 
noncovalent bonds with each other. 
2. Spontaneous polymerization of the fibrin monomers by central (E) regions to lateral (D) 
regions interaction will give birth to oligomers then to protofibrils and further to branched 
polymeric structures [59].  
3. Stabilization of the fibrin network by F XIII. Thrombin activates F XIII which by covalent 
cross-linking adjacent fibrin strings will stabilize the fibrin structure [59].   
The presence of soluble fibrin monomers and polymers in plasma is coupled with early 
phases of fibrin formation after cleavage of fibrinogen by thrombin. These markers have the 
potential to predict thrombosis even in the pre-thrombotic phases, but the cut-off values are 
not yet defined [39]. 
1.2.3.1 Fibrinogen and the quality of the fibrin network 
The quality of the fibrin clot depends on various factors including fibrinogen quantity and 
quality, aside thrombin generation and platelets number and functionality [59]. 
Electron microscopy can visualize the structure of the fibrin network and features like fibre 
diameter and density, as well number and distances between the branch points and the size of 
the pores can be explored and eventually explain clinical implications of different 
abnormalities [59].  
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The porosity and the permeability of the fibrin network can be measured using biophysical 
techniques [59, 60]. These parameters may be influenced by oxidative modifications in the 
fibrinogen molecule which is seen in patients with liver cirrhosis [60]. 
1.2.4 Fibrin involvement in the repairing process of the injured liver tissue 
Fibrinogen, FDPs, and plasmin modulate inflammation and promote repair processes as part 
of the complex interrelation inflation-coagulation following the acute phase response to 
injury [53]. It was suggested recently that intrahepatic fibrin deposition following liver 
surgery is a factor that stimulates liver regeneration and counteracts the postoperative liver 
failure [61]. 
 
1.3 COAGULATION IN LIVER FAILURE 
Liver insufficiency is characterized by complex haemostasis abnormalities which, besides 
many similarities, have distinct characteristics for different clinical entities.  
Many proteins with function that promote or inhibit the coagulation system are synthetized 
by the liver and a decrease of the liver synthetic capacity may affect their plasma 
concentration.   
The liver synthetic function is affected in chronic or acute liver diseases or after extensive 
surgical liver resections. Liver insufficiency and overlapping pathophysiological mechanisms 
such as hypersplenism or endothelium activation will result in substantial changes in the 
haemostatic system.   
1.3.1 Coagulation in chronic liver insufficiency 
1.3.1.1 Primary haemostasis 
Low platelet counts are frequently present in patients with liver cirrhosis due to multiple 
reasons, such as splenic and hepatic sequestration, low thrombopoietin levels and activity, or 
antiplatelet autoantibodies [9, 62, 63].  
Platelets in cirrhotic patients may be dysfunctional, complex defects regarding platelets 
adhesion and aggregation as well concerning receptors and mediators have been reported [9, 
64, 65]. However, many of the earlier studies are questioned due to methodological faults 
[66-68]. A newer report provides evidence for increased platelet activation in vivo conditions, 
still it is not enough to elucidate the enigma of normality or abnormality of platelet function 
in chronic liver disease [67-69]. 
A remarkable observation regarding the platelet function in liver cirrhosis is related to their 
adhesion function [65]. In these patients von Willebrand factor (vWF) have lower than 
normal binding capacity to platelets (via receptor glycoprotein Ib) and collagen [65]. 
However, the platelets (from patients with cirrhosis or normal controls) suspended in plasma 
from cirrhotic patients demonstrate hyper-adhesion to collagen under flow conditions and this 
is attributed to the high plasma concentration of vWF [65]. In cirrhotic plasma vWF antigen 
levels are higher than normal and correlates with the Child-Pugh score, presenting 
substantially increased levels in end-stage liver disease and this is suggested to overrun the 
deficit in its function [65].  
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Additionally, the vWF-cleaving protease ADAMTS-13 has a lower than normal activity [65] 
especially in end-stage liver disease [65]. Subsequently, this deficit contributes to the higher 
levels of vWF [62].    
Even though platelet dysfunction in CLD is not entirely understood and a subject of 
controversy [67], most experts agree that thrombocytopenia may be compensated, at least 
partially, by higher levels of vWF in stable liver cirrhosis [17, 66].  
1.3.1.2 Secondary haemostasis  
In CLD the pro-coagulation factors which are synthetized by the liver are at lower than 
normal plasma levels; factor VIII (fVIII), apparently produced by the liver sinusoidal 
endothelial cells and not by the hepatocytes [70, 71], have higher than normal plasma 
concentrations [70]. High fVIII levels are in relation with increased levels of vWF that binds 
fVIII restraining thus its clearance [70, 72]. 
At the same time, naturally occurring anticoagulant proteins, specifically protein C, protein S 
and antithrombin (AT) have low plasma concentrations [73]. In addition, the function of AT 
and protein C may also be decreased in advanced stages of liver disease [74]. Tissue factor 
pathway inhibitor (TFPI), which is synthetized by the endothelium and not by the liver, has 
normal concentrations but decreased anticoagulant activity due to low levels of protein S (its 
cofactor) [75].  
Because of these concomitant modifications in both pro and anticoagulant pathways the 
generation of thrombin is unaltered (or even enhanced) in stable liver cirrhosis [76-78]. 
1.3.1.3 Fibrinolysis 
Many of the pro- and anti-fibrinolytic factors are synthesized and cleared by the liver and 
therefore affected by liver insufficiency [17]. Thus, the levels of fibrinolytic factors 
dependent of liver synthesis such as plasminogen, α-2 antiplasmin, thrombin-activatable 
fibrinolysis inhibitor (TAFI) have low plasma concentrations while others, synthesized by the 
endothelium, are increased (e.g.  tPA) [79]. PAI-1, which is likewise removed by the liver, 
sometimes shows high plasma levels due to elevated endothelium production especially in 
cholestasis [80] and non-alcoholic steatohepatitis (NASH) [81].  
These disturbances may and will in certain circumstances unbalance the fibrinolytic system. 
However, there is no obvious correlation between the degree of liver insufficiency and the 
degree of fibrinolysis malfunction [17]. 
1.3.1.4 The concept of re-balanced coagulation in liver cirrhosis and the global 
coagulation assays 
Until the early 2000s the standard view on cirrhotic patients assumed that a prolonged 
prothrombin time (PT) and international normalized ratio (INR) combined with a low 
platelet count was associated with a high risk for bleeding, and bleeding prophylaxis with 
plasma and platelets prior surgery was common. On the other hand, per-operative bleeding 
in patients with liver cirrhosis during surgery, and especially during liver transplantation, 
was far less extensive than expected based on the above-mentioned assumptions [64, 73, 82].  
2005 a remarkable finding demonstrated, that thrombin generation is normal in patients with 
liver cirrhosis if thrombomodulin is added to the samples [76]. When the thrombin generation 
test is measured in the presence of activated protein C, which is not happening if 
thrombomodulin is not added, conditions move closer to the in vivo settings and the results 
became surprisingly different [83].  
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Although most of the coagulation factors are low in liver disease, fVIII plasma concentrations 
are increased, which in combination with a low level of the natural anticoagulation factors 
AT, protein C and protein S, maintain a normal or even enhanced, thrombin generation [76, 
78, 84]. 
In the context of a lower than expected blood loss during surgery, demonstration of a normal 
thrombin generation together with platelet hyper-adhesion properties grounded the new 
concept of rebalanced coagulation in CLD [85, 86].  
Conventional coagulation tests such as PT-INR are no longer considered predictors for 
bleeding in patients with liver disease [85, 86], and a patient with stabile liver disease is 
considered being in haemostatic balance even if the so-called standard coagulation tests are 
out of the normal range [79, 87].  
Because thrombin occupies a central role in the coagulation system, a normal thrombin 
generation gives the coagulation system the basis for re-balance [76, 85]. However, in order 
to have functional haemostasis, fibrinogen, the thrombin’s substrate, must be sufficient both 
in terms of quantity and quality [62]. 
Thrombin generation tests (TGT) are the gold standard in the assessment of coagulation 
balance. A limitation is that they can only provide information about the coagulation process 
up to the point of fibrin formation, which does not include platelet function and fibrinolysis. 
[62]. Besides, they are laborious and expensive which limits their use in clinical practice.  
Viscoelastic tests (VETs) on the other hand measure the whole blood clot formation and lysis 
and this can give an advantage in assessment of the coagulation balance.  
It is controversial whether or not fibrinolysis is re-balanced in patients with stable liver 
cirrhosis status[88]. There are observations suggestive for hyperfibrinolysis in stable CLD 
using plasma clot lysis assays [89-91]. In contrast, lack of hyperfibrinolysis in a study 
searching the clot lysis suggests rebalanced fibrinolysis [92]. Fibrinolysis assessed by 
thromboelastometry with the addition of tPA shows absence of hyperfibrinolysis in cirrhosis 
[49].  
An important issue in getting a consensus over the habitual fibrinolysis balance in non-
surgical patients with liver cirrhosis is the difficulty to assess fibrinolysis globally and that the 
clot lysis analyses used are home-made, with limited external validity [74, 88].   
1.3.1.5 The risk of losing coagulation balance in liver cirrhosis 
There is a vulnerability of the coagulation system in liver failure because the rebalanced 
structure has a certain degree of fragility [62].  The low levels of pro- and anticoagulant 
factors narrow the margins to become deficient in these factors at additional liver 
decompensation. Sepsis or renal failure may as well induce imbalances and predispose to 
bleeding and/or thrombosis [62, 86, 93].  
The more advanced liver insufficiency, the more vulnerable the coagulation system will 
become. Particularly in end-stage liver disease (ESLD) imbalances in both directions are 
possible, sometimes with coexisting bleeding and thrombotic events [62].  
The bleeding risk in liver cirrhosis  
Bleeding tendency and even spontaneous bleedings are common complications in advanced 
liver cirrhosis. However, variceal bleeding, the most frequent bleeding complication in liver 
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cirrhosis, is not caused by hypocoagulability but by exacerbations of portal hypertension [85]. 
The magnitude of the variceal bleeding as well depends mainly on the portal pressure [94]. 
As stated above, the clotting time PT-INR has no predictive value regarding the risk of 
bleeding in patients with CLD [62, 85]. This relates to the fact that PT - INR reflects only the 
levels of the procoagulant factors, and not the activity of anticoagulant proteins, platelets or 
fibrinolysis [17]. In this respect PT – INR does not evaluate the coagulation process as a 
whole and therefore cannot assess the balance of coagulation. 
The tendency towards thrombosis and hypercoagulability in liver cirrhosis 
Cirrhotic patients have approximately double the risk of deep vein thrombosis (DVT) 
compared to the general population [95]. Portal vein thrombosis diagnosed with imaging 
techniques has a wide prevalence in different studies of 1-25 % [96, 97], being more observed 
in advanced stages of liver disease [96, 97]. Notably, a prevalence of 2% is reported in 
patients awaiting liver transplantation and 4% in those undergoing liver transplantation [74, 
97].  
In particular cholestasis is associated with hypercoagulability [74, 98]. The autoimmune 
forms of liver disease i.e. primary biliary cholangitis (PBC), primary sclerosing cholangitis 
(PSC), as well autoimmune hepatitis, are associated with antiphospholipid antibodies [99] 
and with thrombosis events perioperatively in liver transplantation [74]. An upregulation of 
certain pro-coagulant factors is described in subgroups of patients with cholestasis [100, 101].  
Also, patients with non-alcoholic fatty liver disease may or may not present a pro-coagulant 
imbalance in different studies, likely due to analytical differences regarding the thrombin 
generation tests methodology [102, 103]. 
It is demonstrated that thrombin generation is higher than normal in end stages of liver 
disease [49, 77] possibly related to resistance to the effects of thrombomodulin [78] , 
predisposing to an imbalance towards hypercoagulability and a pro-thrombotic state [77, 78, 
104]. 
An enhanced platelet count in the presence of high levels of VWF is associated with 
prothrombotic risk, therefore actions to increase platelet count in non-bleeding cirrhotic 
patients should be avoided [105].  
Dysfibrinogenemia.  Fibrinogen synthesized by a liver with advanced liver disease may be 
dysfunctional due to the hypersialylation and is then characterized by a delayed fibrin 
polymerization [106]. Recent studies suggest that in liver cirrhosis fibrinogen molecule, 
because of oxidative modifications, is more thrombogenic and produces a fibrin network 
characterized by reduced permeability which makes the cloth less susceptible to lysis [60].  
1.3.1.6 Intrahepatic activation of coagulation 
Animal and human studies demonstrate presence of intrahepatic activation of coagulation in 
liver disease, which could be a factor in the disease progression [62, 107, 108]. Intrahepatic 
coagulation activation with formation of microthrombi in the sinusoid may be a consequence 
of the tissue factor expression by injured hepatocytes, as suggested by studies in mouse with 
acute induced liver failure [109].  
1.3.1.7 Endothelial dysfunction in liver disease 
In liver failure endothelium suffers a dysfunction under the influence of nitric oxide 
dysregulation and inflammatory disturbances [110]. The levels of coagulation and fibrinolysis 
factors such as fVIII, vWF, PAI-1 and tPA are high and this is related to the endothelial 
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production [74]. Endothelial dysfunction due to endotoxemia and oxidative stress, is 
suggested to play a role in the pro-thrombotic abnormalities in the portal circulation [74]. 
1.3.1.8 Assessment of the coagulation balance using viscoelastic tests 
Viscoelastic tests in stable CLD 
Clinically, VETs are mainly used in patients with liver failure as point-of-care tests to guide 
the administration of pro-coagulant treatment during and after surgery with a high risk of 
massive bleeding. VETs are effective to reduce the administration of blood products in liver 
transplantation [111, 112] and also before invasive procedures in CLD [113]. However, 
VETs have not been proven to predict bleeding in liver failure [62].   
Both thromboelastography (TEG®) and thromboelastometry (ROTEM®) have been used in 
studies to characterize coagulation in patients with liver insufficiency.  In compensated 
patients with chronic or acute liver disease, TEG® demonstrates that the coagulability 
remains in normal ranges [114], while studies performed with ROTEM® show normo- or 
hypocoagulability [49, 115, 116].  
PBC and PSC are associated with thromboelastographic signs of hyperactive coagulation [98, 
117], while HCC in the absence of cirrhosis is not [118].  TEG® can detect 
hypercoagulability in liver cirrhosis [98, 117], but there are no such reports for ROTEM®.  
It should be emphasized that TEG® and ROTEM® results are sometimes conflicting, which 
could de explained through differences in sensitivity [119, 120]. 
The viscoelastic coagulation profile in decompensated liver failure  
Studies including viscoelastic coagulation description in decompensated chronic liver disease 
are rare.  In a study on acute decompensated chronic liver disease TEG demonstrates 
imbalance of the coagulation with hypo-coagulability in most parameters compared to 
healthy controls [121]. 
A recent study, using ROTEM®, compared patients with acute-on-chronic liver failure 
(ACLF) with patients in acute decompensation of the liver disease (AD) [122]. Hypo-
coagulability in three or more ROTEM® parameters, is observed to a greater extent in 
patients with ACLF (60%) than AD (30%), hypercoagulability is exceptional [122]. The 
ROTEM® parameters are not significantly changed at 72 hours after admission [122]. 
Patients with ACLF have a higher prevalence of bleeding but this is not correlated with hypo-
coagulability on ROTEM® parameters in this study [122]. INR and aPTT are significantly 
higher in ACLF and correlated with mortality [122]. Platelets and fibrinogen concentrations 
are more affected in ACLF than AD [122]. 
In another study fibrinolysis in patients with ACLF and AD, explored with a global 
fibrinolysis test which could indicate the risk for thrombosis in case of hypofibrinolysis, show 
a large variability with patients in normo-, hypo- and hyperfibrinolysis state [123]. In this 
study hypofibrinolysis is associated to sepsis, organ failure and higher mortality [123]. 
1.3.1.9 Thromboelastometry (ROTEM®) and assessment of prognosis in chronic liver 
failure  
Since the early 2000s, the reliability of PT-INR, as the only coagulation test included in the 
Child-Pugh score and Model for End-stage Liver Disease (MELD) score is questioned [73, 
124]. Due to the high interlaboratory variability for INR, there are concerns over the impact 
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of an uncertain  INR on the MELD score and further on the objectivity in the evaluation of 
priority to liver transplantation [86, 125, 126]. 
In one of the few published studies using viscoelastic tests in patients with stable CLD, it is 
suggested that thromboelastometry, particularly maximum clot firmness (MCF), may be 
useful in assessing prognosis in patients with stable CLD [115]. The reason is that parameter 
MCF correlated with Child-Pugh and MELD scores similarly to PT-INR [115]. Another 
study, published in 2016, show a good correlation between MCF and MELD but concludes 
that ROTEM® is inappropriate to assess global haemostasis in liver cirrhosis [116]. Both 
studies included patients with liver cirrhosis based mainly on viral and alcoholic aetiology 
with the greater part of the patients in earlier stages of liver disease according to Child-Pugh 
and MELD scores. 
A recent study (published 2018) reports a significant association between the parameter CT 
(on INTEM and EXTEM) and increased mortality in patients with acute-on-chronic liver 
failure [122]. 
There are so far no reports on patients with an indication for liver transplantation. 
1.3.2 Coagulation in acute liver insufficiency 
Diagnosis of acute liver failure (ALF) require, by definition, a PT- INR ≥1.5 and the presence 
of encephalopathy [127]. 
Compared with liver cirrhosis, patients with acute liver insufficiency exhibit a higher 
reduction in pro-coagulant factors reflected by the substantially higher PT-INRs, and also a 
lower level of the anticoagulant proteins AT and protein C [127]. Conversely, high levels of 
fVIII and vWF are present, as well as a low ADAMTS13 concentration in plasma [127]. 
Thrombocytopenia is common in acute liver failure, however not as pronounced as in chronic 
liver failure [114, 128]. 
In contrast to liver cirrhosis, fibrinolysis is lower than normal in acute liver insufficiency, 
with impeded lysis activity on the overall fibrinolysis potential tests [129].  
Coagulation in acute liver insufficiency is re-balanced almost in the same manner as in CLD 
with tendencies rather towards thrombosis than to bleeding [127]. Thrombin generation is 
normal [129] and TEG show most normal clot formation, and even hypercoagulability if 
sepsis is associated [130]. 
Patients with ALI rarely present significant spontaneous bleedings [127, 131], or massive 
bleedings during liver transplantation [131]. 
1.3.3 Coagulation changes following major liver surgery 
The haemostasis abnormalities associated with major liver surgery are complex and not 
thoroughly elucidated. A better description of the coagulation processes in these patients is 
desirable.   
Major hepatic resections are associated with postoperative liver dysfunction, which in most 
cases is spontaneously reversible in a relatively short time period (days) [132, 133]. During 
this time, however, coagulation abnormalities are present.  
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1.3.3.1 The risk of bleeding in connection with liver surgery 
Most centres routinely follow conventional coagulation tests in the postoperative period after 
major liver surgery. A higher than normal PT-INR occurs immediately postoperatively in the 
majority of cases [132, 134]. This sudden increase of PT-INR is often interpreted as an 
increased bleeding risk and this sometimes results in prophylactic plasma administration. 
Furthermore, concerns over the risk for postoperative bleeding is the background to the 
controversy whether postoperative thrombosis prophylaxis can or cannot be administered to 
these patients [135, 136].  
The perioperative bleeding incidence in retrospective studies is low, around 6% [137, 138], 
and postoperative transfusions are only given in 0.8 % of cases [139]. In this respect, it is 
questionable if PT-INR alone is good to assess the postoperative bleeding risk after major 
liver resections. 
1.3.3.2 The risk of thromboembolism in connection with liver surgery 
In contrast to the low risk for postoperative bleeding following hepatic surgery, there is an 
increased prothrombotic risk. The incidence of deep venous thrombosis (DVT) is between 
0.8% and 3.6%, and of pulmonary embolism (PE) between 1.4% and 7.1% [135, 139, 140]. 
The highest probability to occur for venous thromboembolism (VTE) is between 
postoperative days 5 and 7 after major liver resections [140, 141]. On a multivariate analysis 
(n= 375,748) the patients undergoing hepatectomy has among highest odds ratios (2.55) of 
developing VTE, higher than nephrectomy (1.19), colorectal surgery (1.87), pancreatectomy 
(2.07) or even esophagectomy (2.47), relative to bariatric surgery which has the lowest risk 
for VTE [142].   
There are evidences of postoperatively increased levels of coagulation activation markers 
such as prothrombin fragments 1 and 2, or thrombin-antithrombin complexes in living liver 
donators or liver resections for primary and secondary malignancies which are indicating a 
hypercoagulable state [134, 143]. In addition, a hypofibrinolytic state early postoperatively 
following liver resections is described recently, in the same extent as following pancreas 
resections [144].  
It is also reported a decline not only in pro-coagulant factors, but also in anti-coagulant 
proteins such as AT and protein C during the postoperative days following major liver 
surgery [118, 134]. It has been unclear if this is a factor contributing to the high 
prothrombotic risk in these patients.  
A systematic review reports that thrombosis prophylaxis in patients with liver resections 
decrease the incidence of VTE events from 4.6 % to 2.6 % [145]  
1.3.3.3 Global coagulation testing in major liver surgery 
Thrombin generation tests postoperatively after hemihepatectomy show contradictory 
results, with increased as well normal values in different studies [146, 147]. 
Viscoelastic testing. TEG® is studied postoperatively in patients with major liver resections. 
In living liver donors, TEG® indicates hypercoagulability [148]. In patients undergoing 
major liver surgery mainly for malignancy a hypercoagulable state on postoperative day one 
(defined as decreased R-value on TEG®) that returned to the preoperative values in the 
following postoperative days is reported [149]. This is not reported by another study 
following liver resections in patients with hepatocellular cancer TEG® which shows 
normocoagulability with no signs of hypercoagulability postoperatively [118]. Despite the 
signs of hypercoagulability on TEG, none of these reports’ present associations with 





2.1 STANDARD COAGULATION TESTS  
A standard laboratory evaluation of the haemostasis consists of a battery of a few 
conventional tests which are usually performed in patients at risk or presenting bleeding of 
different grades that needs treatment.  
2.1.1.1 The prothrombin time (PT) 
The prothrombin time (PT) test was developed by Armand Quick who published the original 
method in 1935 [150].  
His methodology conformed to contemporary theory on haemostasis that thrombin results 
from prothrombin in the presence of thromboplastin and calcium [151]. At that time the 
clotting time of the recalcified plasma was already described, Quick tested different 
thromboplastins (tissues extracts) to get more constant results [151]. 
The PT test measures thus the time required for a clot to begin to form, once the protein 
called tissue factor and calcium are added to citrated platelet-poor plasma. Adding in excess 
thromboplastin (which contain tissue factor, and phospholipids) to plasma, clotting time will 
be dependent only on the prothrombin level (in conditions in which calcium level is constant) 
[150, 151].  
Noticeably, the methodology does not cover the part of the coagulation system that is affected 
by haemophilia and PT is normal in these patients. On the contrary, the test is prolonged in 
patients with “obstructive jaundice” which allowed Quick to conclude that prothrombin 
levels are decreased in these patients [150].  
However, the PT test is sensitive to changes in coagulation factors II, V, VII, X, and 
fibrinogen [86]. 
Depending on the method used to run the test, thromboplastin may either be plain (extractive 
or recombinant), as used in the Quick method or combined with “additives”, as used in the 
Owren method [152].  The Owren method use as additives factor V and fibrinogen together 
with the tissue factor, making the PT test specific only to factors II, VII and X [152]. This 
makes the PT more precise by eliminating two variables and lowering the inter-laboratory 
variability in patients with chronic liver disease [153]. 
PT results have a large coefficient of variation between different testing centres, due to the 
differences in the quality of the thromboplastin which is supplied by many different 
manufacturers. This makes it extremely difficult to monitor PT in patients treated with 
vitamin K antagonists (VKA). The inconsistencies in results led to the development of a 
method of standardization [154]. 
International normalized ratio (INR) 
The standardization of PT occurs according to a system of calibration recommended by The 
World Health Organization (WHO) [155].  
Each manufacturer of commercial PT systems must calibrate its regent (recombinant human 
thromboplastin or thromboplastin of bovine or rabbit origin) against one of the WHO 
international standards. PT is measured in normal subjects and in patients treated with 
vitamin K antagonists, using both the actual reagent and a WHO reference reagent. The 
results (pair values) are plotted on a log-scale and a regression line is drawn. The slope of the 
 
18 
line is calculated, and the result is the correction factor named International Sensitivity 
Index (ISI). 
The ISI is used to convert the PT results obtained into the international scale called 
International Normalized Ratio (INR), as follows: 
INR= ( PTpatient/PTnormal)ISI [155] 
The INR scale is most accurate in the range of 1.5–4.5[86]. 
It is important to emphasize that ISI (implicitly INR) is valid only for patients on vitamin K 
antagonists [86]. 
Significant differences have been reported between the INR calculated with an ISI for the 
patients on vitamin K antagonists, and the INR based on ISIliver , calculated for patients with 
liver cirrhosis [156].  
The International Society on Thrombosis and Haemostasis (ISTH) is aware of these 
differences but a standardization of the INR in liver disease is regarded too laborious to be 
carried out currently [157]. 
2.1.1.2 Activated partial thromboplastin time (aPTT) 
The test called partial thromboplastin time (PTT) emerged from the need to quantify the 
coagulation defect in haemophilia (as PT test was insensitive to haemophilia). Observations 
over the clotting time of plasma with reduced levels of thromboplastin showed that 
considerably longer clotting times could discriminate haemophilic plasma from normal [158]. 
A new clotting time test was designed based on this finding and the term used for this new 
test was partial thromboplastin time.  An important drawback for PTT was the considerable 
variability. By adding kaolin as the activator, more stable clotting time was achieved, with a 
better reproducibility [159]. This test was named activated PTT (aPTT). 
aPTT is sensitive to the deficiencies of the intrinsic pathway factors II, V, VIII, IX, X, XI and 
fibrinogen.  
2.1.1.3 Platelet count 
Clinically, the platelet count is in many cases the only investigation necessary to assess 
platelet contribution to haemostasis, except for situations involving antiplatelet therapy or 
acquired or hereditary platelet dysfunctions in which case platelet function testing is 
mandatory.  
Platelet count is currently performed using impedance measurements by automated analysers 
[160]. The normal range for platelet count is between 150,000-400,000 /μL. 
2.1.1.4 Fibrinogen plasma concentration 
Automated assays are available to perform this test according to the Clauss method. With 
this method, fibrinogen concentrations are evaluated indirectly. What is measure is the time to 
fibrin formation when thrombin in excess is added to diluted plasma samples. Fibrinogen 
plasma concentrations are calculated then using calibration curves [161]. Although there are 
reports indicating variability of the assay between laboratories, Clauss fibrinogen correlates 
well with other coagulation assays both in healthy subjects and patients with 
dysfibrinogenemia [162]. It is reported that haemodilution with hydroxyethyl starch (HES) 




2.1.1.5 Quantitative D-dimer  
D-dimer are quantified using automated immuno-turbidity assays. D-dimer is formed through 
fibrinolysis and is a very sensitive marker for the activation of coagulation [164]. D-dimer 
increases postoperatively [165] or in any conditions associated with elevated fibrin-formation 
such as massive bleeding, venous thromboembolism (VTE) or disseminated intravascular 
coagulation (DIC), but also in inflammation, malignancies or pregnancy [35] (p13).  Being 
present in many pathological conditions not necessary associated with VTE, D-dimer have 
low specificity for pro-thrombotic states [164]. However, because of high sensitivity, D-
Dimer plasma values < 500 μg/L have negative predicting value for VTE [38, 164]. The 
effectiveness of VTE diagnostic becomes higher if the cut-off value is age-adjusted [40]. 
2.1.1.6 Antithrombin, protein C, protein S 
Functional assays measure the inhibitory activity of anticoagulant proteins on their substrates. 
For AT it is measured the activity against fXa, for protein C and S the activity against fVIIIa 
and fVa[26].  Quantitative antigenic assays measure their concentration in plasma [26]. 
2.1.1.7 Limitations of SCTs 
The standard coagulation tests are well standardized and, despite signalled variability, they 
are adequate for analysing punctual aberrations in the coagulation system and are effective in 
cases with clear, unequivocal reasons for coagulation non-normality.  
When complex coagulation disturbances occur, the assessment of the coagulopathy is more 
challenging. It is the case of massive bleeding associated with trauma or different surgical 
interventions, as well in liver insufficiency, which implies multiple concomitant coagulation 
abnormalities. In these situations, the fragmented information given by the SCTs is not 
enough for a global evaluation of the haemostasis. 
 
2.2 VISCOELASTIC TESTING 
2.2.1 Introduction 
1948 Dr. Hellmut Hartert published the principles of thromboelastography (TEG), a 
technique able to measure the phases of blood coagulation during clot formation [166]. The 
attribute of measurement was the viscoelasticity of the blood and its changes over time, 
which was graphically depicted by an ingenious and simple oscillatory mechanism.  The 
trombelastographic principle is currently used in the computerized version of the TEG® 
(Haemonetics, Braintree, USA).  
In 1996 the thrombelastographic principle was adapted, and a new technique invented, 
namely rotational thromboelastometry (ROTEM®) [167].  
The generic term of viscoelastic coagulation tests (VETs) is common when we refer to 
TEG® or ROTEM® or other similar techniques which investigate viscoelasticity during clot 
formation.  
Viscoelastic tests investigate the coagulability of the whole blood, which contains all the 
protein, enzymatic and cellular components involved in coagulation and fibrinolysis. Hence, 
VETs give a global assessment of the coagulation function and, although several components 
are missing, reflects better the in vivo haemostasis [168].  
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2.2.1.1 The TEG® and ROTEM® techniques.  
Although TEG® and ROTEM® are related and share similarities, there are significant 
differences between the two systems, in terms of both mechanical and software operation, as 
well as differences in activators and additives [168, 169].   
TEG® detects the viscoelastic changes of the whole blood using a bowl which oscillates 
around a plunger connected to a torsion wire, while ROTEM® uses a pin axis which 
oscillates in a cuvette [170].  
The ROTEM® modification in which the pin axis is stabilized with a ball bearing, which 
reportedly can avoid movement artefacts, gives greater robustness than TEG® [169].  
For conversion of the movements in items of information TEG® is equipped with an 
electromagnetic transducer-amplifier while ROTEM® has an optic sensor [170]. 
The collected data is processed by a computer and the viscoelastic changes which occur 
during coagulation are visualized by a graphic representation of clot formation and lysis. A 
set of parameters is delivered, giving information about the times until different levels of 
coagulation are achieved and the mechanical strength of clot (viscoelasticity) which is 
illustrated as amplitudes of the graph [170].  
2.2.2 The ROTEM® device. The thromboelastometric curve and its 
parameters. ROTEM® analysis 
2.2.2.1 The ROTEM® delta device 
ROTEM® delta is a semiautomatic device with 4 independent measurement channels that 
allow the parallel plotting of four different thromboelastographic curves. 
During the analysis, the pin is inserted in the sample which is placed in a cuvette fixed in a 
metal cup, with a temperature that can be controlled. Usually, the temperature is set at 37 
degrees Celsius.  The pin axis oscillates 4.75 degrees 12 times per minute. The clot fibres 
formed after coagulation initiation, bind the pin to the cuvette wall impairing the pin rotation 
as the clot strength increases in intensity. This reduction in the movement of the pin is 
measured and presented graphically as amplitud [167].  
The pin movement is detected by a LED light detector via a mirror mounted on the moving 
axis. The signal from the light detector is electronically processed by the embedded computer 
and thus the thromboelastometric curve is generated. The device is equipped with an 
electronic display showing the progressive thromboelastometric curves and 
thromboelastometric parameters (p.40 in [35]).  
2.2.2.2 The thromboelastometric curve and its parameters on ROTEM® delta device 
The thromboelastometric curve is plotted against x/y axis where x is the time (in seconds) and 
y is the amplitude (in millimetres). The amplitude reflects the clot strength, or more 





Figure 3. Parameters of the thromboelastometric curve (Graphics created using 
PowerPoint) 
This graphic representation is depicted as a mirror image with the positive values 
extrapolated in the negative area of the graph so that the image is symmetrical and imitate the 
image generated by thromboelastography in its mechanical, non-computerized model. 
The standard thromboelastometric parameters are (p 43 in [35]): 
Coagulation time (CT) is the time in seconds from the start of measurement until the clot 
firmness reaches 2 mm in amplitude; 
Clot formation time (CFT) is the time in seconds between clot firmness 2 and 20 mm; 
The alpha (α) angle (degrees), is the angle formed by the tangent to the graphical trace at an 
amplitude of 2 mm; 
A5, A10, A20 - the amplitude in millimetres reflecting the clot firmness after 5, 10 and 20 
min; 
Maximum clot firmness (MCF) - is the amplitude in millimetres reflecting the maximum 
clot firmness reached during the time the analysis is running; 
Maximum lysis (ML) - presented as a percentage of MCF- represents the maximum decay in 
amplitude reported to MCF and reflect the maximum lysis detected during analysis (usually 
this value is reached at the end of the analysis); 
Lysis index at 30 and 60 min (Li 30, Li 60) - presented as a percentage of MCF - represents 
the decay in amplitude reported to MCF after 30 and 60 min from the analysis start. 
Depending on the phase of the coagulation which is investigated, the parameters can be 
classified as: 
Coagulation activation and clot polymerization parameters: CT, CFT, The alpha (α) 
angle; 
Clot firmness parameters: A5, A10, A 20, and MCF; 
Clot lysis parameters: (which reflect the residual clot firmness) – Li 30, Li 60, ML. 
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2.2.2.3 ROTEM® analysis  
The blood for ROTEM® analysis is collected on citrated samples.  
Activation of coagulation. For analysis, the samples are recalcified and activation of 
coagulation is made in two ways, with tissue factor which investigate the extrinsic pathway 
(the thromboelastometric curve which results is called therefor EXTEM) or ellagic acid and 
phospholipids for the intrinsic pathway (which initiate the thromboelastometric curve called 
INTEM) [35]. 
Different additives can be used to investigate different coagulation aspects. 
Fibrinogen polymerization is assessed by adding Cytochalazin-D to block the platelets 
activation in the sample, while coagulation is initiated through the extrinsic pathway (hereby 
the analysis is a modified EXTEM). The thromboelastometric curve which results is called 
FIBTEM [35].  
To diagnose hyperfibrinolysis and discriminate between fibrinolysis and other reasons for 
hypo-coagulability, an inhibitor of fibrinolysis can be used. Commonly Aprotinin is added to 
inhibit fibrinolysis while coagulation is initiated through the extrinsic pathway (thus the 
analysis is a modified EXTEM). The thromboelastometric curve which results is called 
APTEM.  More recently tranexamic acid was introduced instead of Aprotinin, and the 
analysis is called tAPTEM [35]. 
To reveal heparinization or heparin-like effects, Heparinase can be used in the sample while 
coagulation is initiated through the intrinsic pathway (thus the analysis is a modified 
INTEM). The thromboelastometric curve which results is called HEPTEM [35]. 
2.2.2.4 The ROTEM® reference ranges 
ROTEM® reference values were obtained from a large multicentre study in healthy 
volunteers [171].  
Reference ranges reported in several studies are for orientation only because they can vary 
marginally from country to country (p.42 in [35]). It is recommended that each centre should 
validate the reference ranges [168]. 
2.2.3 Interpretation of ROTEM® analysis 
2.2.3.1 Coagulation activation and clot polymerization parameters  
The parameter CT in all ROTEM® analysis is the time between when the coagulation is 
activated until the clot network is of enough strength to restrain the movement of the pin. 
This parameter is influenced by the plasma level of the coagulation factors and their activity 
and reflects partially the thrombin generation process. It is thus influenced by anticoagulants 
and tissue factor expression on circulating cells (p.44, 52-54 in [35]). 
CT INTEM mainly depend on coagulation factors of intrinsic pathway (p.42 in [35]). A 
prolonged CT INTEM is interpreted as a lack of coagulation factors involved in the intrinsic 
pathway. A shortened CT in HEPTEM compared to INTEM of the same analysis represent a 
heparinization effect. 
CT EXTEM depend on coagulation factors of extrinsic pathway II, V, VII, X, as well on 
fibrinogen (p.41 in [35]).  A prolonged CT EXTEM is interpreted as a lack of extrinsic 
pathway coagulation factors and can be used to guide the administration of coagulation 
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factors concentrate or plasma. In non-cirrhotic patients treated with warfarin CT EXTEM 
linearly correlates with PT-INR [172]. 
CFT and the alpha (α) angle in all ROTEM® curves reflects the kinetics of the clot 
formation and their velocity depends to a great extent on thrombin generation, but the 
contribution of fibrinogen-platelets functionality in these parameters is important (p.43 in 
[35]). In INTEM/EXTEM these parameters alone cannot discriminate deficits of fibrinogen 
from platelets [173]. Discrimination can be made by comparing clot firmness parameters 
from EXTEM and FIBTEM (p.54 in [35]). 
2.2.3.2 Clot firmness parameters  
Both in EXTEM and INTEM clot firmness parameters A5, A10, A20, and MCF reflect 
fibrinogens and platelet's contribution to the formation and stability of the clot. Lower than 
normal values of these parameters are interpreted as lack of fibrinogen and/or platelets. MCF 
have been used in the decision-making algorithms regarding treatment of severe bleeding; A5 
and A10 are reported to correlate very well with MCF and thus allow a much earlier decision 
for treatment [174, 175], and have recently been included in algorithms [176, 177]. 
In FIBTEM the clot firmness only results from the fibrinogen polymerization because the 
platelets activation is blocked. Thus, the difference between clot firmness in EXTEM and 
FIBTEM can give an estimation of the platelet's contribution to the clot strength (p.54 in 
[35]). 
Higher than normal values of clot firmness parameters, are interpreted as hypercoagulability 
[178, 179]. 
2.2.3.3 Clot lysis parameters  
These parameters which are calculated for all ROTEM® analysis (INTEM, EXTEM, 
FIBTEM, etc.) give information regarding the activity of the fibrinolytic system. They 
indicate the residual clot firmness reported to MCF at different subsequent time points, 
usually at 30 and 60 min during the test run. The parameter ML is usually achieved at the end 
of the test and corresponds to Li 60 if the total test time is 60 min.  
Clot lysis parameters are used in detecting hyperfibrinolysis. A higher than normal value 
could indicate hyperfibrinolysis, which is undoubtedly if the value is high.  
It is reported that ROTEM® have a low sensitivity for the disclosure of a clinically relevant 
level of hyperfibrinolysis in trauma patients [180]. 
FIBTEM is more sensitive to hyperfibrinolysis then EXTEM or INTEM [181, 182]. In a 
study EXTEM is more sensitive to hyperfibrinolysis than INTEM [181] 
As fXIIIa stabilizes the clot and increase the resistance to fibrinolysis, higher than normal clot 
lysis parameters on ROTEM® could indicate a deficiency of this coagulation factor (p.45 in 
[35]). However, this could not be demonstrated in patients with liver cirrhosis [183]. 
2.2.4 Limitations of viscoelastic testing 
Limitations are related to the fact that viscoelastic tests are not sensitive to vWF activity and 
that protein C is not activated during the analysis [62].  
A recent trial reports that ROTEM® is not sensitive to von Willebrand disease (vWD) while 
TEG® can discriminate vWD patients from healthy controls [184].  
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VETs are insensitive to antiplatelet therapy effects (p. 45 in [35]). 
Limitations regarding extrapolation to in vivo reality are related as well to the fact that the 
endothelial factor is excluded and that the analysis is not performed under flow conditions 
[79]. 
Another limitation is low sensitivity to fibrinolysis [180, 185]. 
2.2.5 Clinical applications of viscoelastic testing 
2.2.5.1 Viscoelastic testing in clinical situations involving bleeding 
Cardiovascular surgery, liver transplantation, trauma, and obstetric haemorrhage have been 
the main indications of viscoelastic tests as point-of-care (POC) tests for haemostatic 
management in the bleeding patient. 
Cut-off values for the management of coagulation are established in studies conducted with 
both TEG® and ROTEM®, and several transfusion algorithms are published and used per se 
or adapted to the practices of each centre [176, 186, 187]. 
In liver transplantation, VET based algorithms reduce red cell and fresh frozen plasma 
transfusion [111]. ROTEM® improves the use of coagulation factors, especially fibrinogen 
[188], and could also identify patients at risk for postoperative bleeding [189]. In cirrhotic 
patients, TEG® -guided transfusion before invasive procedures decreased the use of blood 
products transfusion compared to INR and platelet count guided protocol [113]. 
Viscoelastic testing has been investigated in smaller trials in other clinical areas such as 
severe sepsis, inherited bleeding disorders, anticoagulation with direct oral anticoagulants 
(DOACs), hypercoagulable states, liver surgery, neonatology and paediatrics, extracorporeal 
membrane oxygenation (ECMO), etc. 
2.2.5.2 Viscoelastic testing and hypercoagulable states 
Viscoelastic tests are used in studies to detect hypercoagulability. TEG® is able to detect 
hypercoagulability after major abdominal surgery and to predict thrombotic complications 
after surgical procedures [190, 191]. 
Furthermore, there are a few reports which show that ROTEM® has potential to diagnose 
hypercoagulability and even predict thromboembolism [35, 179, 192, 193]. Expanded clot 
firmness parameters are most commonly reported to diagnose hypercoagulability [178, 179], 
but shortened CT and CFT could also be appropriate indicators [192].   
 
 
2.3 TRACER METHODOLOGY OF DE NOVO PROTEIN SYNTHESIS 
MEASUREMENT  
The challenge in metabolic research is to investigate the dynamics of the metabolic 
mechanisms and the rates of changes in these processes. Among methods to investigate 
metabolism are isotopic labelling techniques, which allow dynamic measurements and 
remains highly reliable, despite their longevity [194, 195]. 




2.3.1 Isotopic tracers in metabolic research 
2.3.1.1 The term of tracer and tracee 
The term tracee is used to indicate a molecule (the substrate) that is involved in metabolism 
and is itself, or directly related to, the compound of interest for the research.  
The biological behaviour of the tracee can be studied by administrating a traceable molecule, 
called tracer, which mimic the tracee course. Thus, the metabolism of a tracee can be 
estimated by studying the tracer dynamics in vivo if the tracer is metabolically identical with 
the tracee.  
An isotopic tracer is the substrate (the tracee) which is labelled with an isotope. The tracer is 
thus chemically identical to the tracee but also different which make it distinguishable from 
the tracee. 
An essential assumption to get reliable results using isotopic techniques is that the labelling 
does not influence the metabolism and the function of the substrate [194]. The tracer differs 
from the tracee only by physical properties which allows separation, quantification and ratios 
calculation. 
2.3.1.2 Isotopes used for labelling of tracers 
The isotopes of a chemical element have the same number of protons but differ by the 
number of neutrons they contain, which make their atomic masses different. The isotope with 
the lowest atomic mass can be written as M+0 (M from atomic mass) [194]. As the atomic 
mass of a neutron is 1 Da, all the other isotopes can be written as M+i (i=1,2, 3 etc) where i = 
the number of extra neutrons in the isotope as compared with M+0.  
Either radioactive isotopes or stabile isotopes have been used in metabolic research to label 
the tracers [195]. 
When radioactive isotopes are used, the tracer differentiation from the tracee is made by 
using scintillation counters [195]. 
The tracers labelled with stable isotopes can be distinct from the tracee by the differences in 
atomic/molecular mass. Mass spectrometers are used for this purpose.  
2.3.1.3 Stable isotope tracers in metabolic research  
When used in humans, an important advantage of the stable isotopes over the radioactive 
ones is the lack of disintegration and subsequent ionizing radiations. Hence, stable isotopes 
imply no risks or side effects when they are administrated in recommended doses 
(sometimes called “accepted amounts”), allowing even repeated measurements, which in 
most cases is not possible with radioisotopes [195]. 
2.3.1.4 The concept of natural abundance 
The stable isotopes are naturally occurring. For the chemical elements most used as tracers 
(hydrogen, carbon and nitrogen) the most commonly isotopes in nature are those with the 
lowest atomic mass, which are 1H, 12C and 14N respectively [194]. The isotopes 2H, 13C, 15N 
are rare (0.02-1.1 %) [194]. Tracers are labelled with isotopes which are not the most 




2.3.2 Tracer mathematical models (pools, isotopic enrichment) 
Many mathematical models are used to explore the metabolism by using isotope tracers. 
These analytical models aim to represent as accurate as possible the physiology of a 
metabolic process.   
2.3.2.1 Body pools/compartments.  
A pool is a theoretical concept defined as a compartment in the body related to a metabolic 
function [196]. The pools are abstractions which must be thought of apart from concrete 
anatomical structures. 
Regarding metabolism and turnover of proteins, the term of pool is usually referring to the 
compartments containing free (unbound) amino acids as well protein(s) that bound the amino 
acids. 
In the human body there are many extracellular as well subcellular compartments, containing 
free amino acids and/or proteins that bound amino acids. The free amino acids pools do not 
overlap the amino acid bound proteins pools and it is therefore appropriate to distinguish 
between them [196]. 
2.3.2.2 Assumptions in mathematical models  
Considering the complexity of the physiological processes and the difficulties to get samples 
at cellular and especially subcellular levels, several assumptions are necessary in different 
models to complete the analysis.  
For-instance in non-compartment models, all the compartments, or a group of them, could be 
seen as a unique pool and it is then assumed that they are homogenous [196]. This is a 
simplification and the term homogenous could be improper as homogeneity in this case 
involves reaching several balances between the compartments. 
2.3.2.3 The concept of steady-state. Isotopic enrichment 
When an isotopic tracer is administrated its concentration will rise in the different 
compartments of the body. Sooner or later depending on the rate of infusion, a steady state of 
the tracer concentration (enrichment respectively) will be reached in the pool of the free 
tracer [194]. 
The isotopic enrichment is defined as the ratio of abundance of tracer to tracee in the pool of 
interest at a certain time point [194]. Isotopic enrichment parameters express the percentage 
of enrichment of the tracer (%enrichment). 
The primary parameter is the tracer to tracee ratio (TTR) which mathematically is expressed 
by the formula: 
TTR = Tracer/tracee [194] 
There are other ways such as atom percent (%) excess (APE) or mole percent (%) excess 
(MPE) which are used to express the isotopic enrichment.  
APE= [TTR/ (1+TTR)] x 100 [194] or 
APE (MPE) = [tracer/ (tracer + tracee)] x100 [194] 
Thus, APE (MPE) are derivatives of TTR. 
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The term used for the tracer steady state enrichment is “plateau enrichment” (Ep) [196]. 
2.3.3 The tracer incorporation model 
The incorporation model is used to assess the in vivo synthesis of a molecule. This model can 
be applied in studies of de novo synthesis for individual proteins [194].  
The term de novo synthesis refers to a complete creation of a molecule and is opposed to the 
process of synthesis by recycling. For protein synthesis it refers to the ribosomal translation 
of RNA to a protein [196].  
After its administration, usually intravenously, the tracer enters the amino acid pool for 
protein synthesis and is incorporated in the protein which is the subject of research. In this 
process the amino acid is called a precursor whereas de novo synthetized protein is the 
product [194]. 
The incorporation model contains an important assumption that the size of the total pool and 
the incorporation rate after the administration of the tracer does not change during the time of 
the study [194]. 
2.3.3.1 Administrating the tracer  
The tracer can be given either orally or intravenously. Mostly the intravenous administration 
is used to determine protein synthesis. One or more tracers can be infused during a certain 
time interval. 
There are a few ways to intravenously administrate the tracer which settle the names to 
specific methods.  
1. The constant infusion method. The tracer is then administered at a constant rate. An 
inconvenience is that the steady state will often not be achieved until after a long time period 
(most often several hours of infusion). A large number of samples are necessary just to assure 
that the steady state has been achieved, and the patient should then be maintained in a 
metabolic steady state during this extended period [195, 197]. Another disadvantage with this 
method is the so called “precursor problem” which is presented below. 
2. Primed continuous infusion method. Here a bolus of tracer is given to quickly reach the 
steady state, followed by a continuous infusion to maintain it [194]. 
3. A large unique bolus (The flooding dose technique): The tracer is administrated 
intravenously in a pulse dose which compulsorily equilibrate to steady state the enrichment of 
the tracer in all compartments [197]. An important advantage is that the measurements are 
performed under a shorter time which is necessary in clinical situations with rapid changes in 
metabolism. A potential disadvantage is that the flood in itself may affect what is supposed to 
be measured. 
2.3.3.2 Sampling 
Samples should ideally be taken from the pools in which the tracer show the greatest 
amplitude of dilution [195]. 
Repeated samples are taken. The interval of sampling depends on the flow and transit time of 
the tracee and its tracer trough the organ which synthetize the protein, the time needed to 
achieve steady state and the presumed rate of incorporation of the tracer into the protein 
[195].   
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Plasma and tissue sampling are commonly used for free amino acids enrichments. To explore 
the synthetic rates of proteins which remain intracellularly tissue sampling is needed to 
determine the enrichment of tracer into protein [195].  
For proteins which are exported in plasma such as albumin or fibrinogen plasma samples can 
be used to determine enrichments both for the precursor and the product [198].  
2.3.3.3 Calculations 
For calculation of the protein synthesis rate two sets of variables are necessary: 
1) The precursor enrichment-The isotopic enrichment of the free amino acid in in the 
precursor pool  
2) The product enrichment-The enrichment of the amino acid incorporated into the protein. 
By the methods of constant infusion and primed continuous infusion the protein synthesis rate 
can be mathematically calculated by dividing the protein enrichment to the area under the 





Δ Eprotein= change in protein enrichment 
∫Ep = area under the curve for precursor enrichment 
t= time 
2.3.3.4 The precursor problem 
A core problem in metabolic research using isotope labelling for assessment of protein 
synthesis is the adequately sampling of the pool of interest. It is important to accurately 
indicate the precursor enrichment in the appropriate pool in order to get realistic estimations 
of the protein synthesis [195]. 
The “precursor problem” emerge from in the fact that the real precursor pool for protein 
synthesis is the aminoacyl-transfer-RNA (tRNA) pool [199, 200] which is extremely difficult 
to reach and get sample for measurements [200].  In intracellular pools, near the ribosomes 
we don’t have access for sampling and the dilution of the tracer is unknown [195].  
De facto, most studies do not take samples from the aminoacyl-tRNA pool but use samples 
taken at “distance” from the real precursor pool and estimate the processes ongoing in the real 
precursor pool. The assumption is that the intracellular amino acid pool is homogenous in all 
compartments including the site of protein synthesis. This enable to extrapolate the isotopic 
enrichment from tissue (and even plasma) samples to the aminoacyl-tRNA pool [194]. 
However, it is known that the amino acid pool is not homogenous in the subcellular 
compartments [196]. 
The precursor problem consists in the fact that, in the constant infusion technique the plasma 
level of precursor enrichment differs significantly from the intracellular levels [196, 197]. 
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The precursor problem concern as well the source of the tracer at the site of protein synthesis 
in long-lasting continuous infusions. If enough time have passed after the start of tracer 
administration, breakdown of the molecules that already have incorporated the precursor 
release precursors which re-enter the amino acid pool [197].  
With regard to these problems concerning the precursor pool enrichments, questions over the 
accuracy of the results obtained with the continuous infusion method have been raised and 
the flooding dose technique emerged as a solution [197]. 
2.3.4 The flooding dose technique (FDT) 
The flooding dose technique (FDT) was developed to discard the inconveniencies with the 
constant infusion method, in particular the precursor problem [197].  
In the flooding method the precursor is administrated intravenously as a single large bolus of 
a mixture of tracee and tracer. This pulse dose eliminates the differences between the tracer 
enrichments in the free precursor pool and the real precursor pool [201, 202] and give the 
advantage for a more accurate estimation of the real precursor pool [197]. 
If a large amount of a known mixture of labelled and unlabelled amino acid (much larger than 
the endogenous amino acid free pool) is administrated, this will flood the endogenous amino 
acid free pool and provide a uniform enrichment [202, 203].  
The method was used for the first time on mice to study the protein turnover in different 
tissues using radio-isotopes, initially 14C-leucine [204],3H-Valine, then L-[4-3H] 
phenylalanine [205]. Following 10 years of refinement on different animal species, the 
method was applied in humans using stable isotopes [197]. As precursor was used 13C-
Leucine [206, 207], L-[1-13C] phenylalanine [207] and finally 2H5-phenylalanine [201, 208].  
The flooding dose induce a high peak in plasma precursor enrichment. The reached levels of 
precursor enrichment are far above the steady-state. An enrichment equilibrium in all the 
body pools (plasma/tissue/t-RNA) will accomplice in a very short time interval [209].   
Not being dependent on a steady state this method is appropriate to study unstable clinical 
states like in perioperative or critically illness situations [197, 202].  
In humans the precursor enrichment falls after the initial peak at rate of about 25% per hour 
[201]. This is not a problem as the precursor free pool after the bolus injection is much larger 
(several fold) than what normally is [197]. Despite rapid falling, the initial very high level of 
precursor enrichment will allow enough time for sampling. 
An important assumption in the FDT is that the protein synthesis is not altered by the 
administration of amino acids in a pulse dose. Because the calculated fractional synthesis 
rates were larger using flooding dose compared with the constant infusion rates of tracer, 
aroused the supposition that the high amounts of amino acid could stimulate the protein 
synthesis [210]. Studies on skeletal muscle protein synthesis infirmed this hypothesis [197].  
FDT have been used to assess protein synthesis in different tissues (such as liver or muscles) 
both in normal and pathological conditions [197, 202]. 
2.3.4.1 Precursors used in FDT 
The precursor is preferably an essential amino acid. Non-essential amino acids are 
problematic when used as tracers in FTD for protein synthesis assessments as they are 
synthetized de novo in the organism and will give less accurate results.  
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At the outset of the FDT method 13C-labelled leucine was mainly used because of its free 
pool of small size which allow a rapid achievement of steady state in continuous infusion 
techniques and because leucine assure a very good agreement between enrichments in plasma 
and liver tissue [210]. But leucine has been reported to stimulate protein synthesis in muscles 
[211] and affect nitrogen balance during starvation [212]. Moreover, the precursor 
enrichment was possible to determine by using GC-MS but the enrichment in protein 
necessitate more sensitive instruments such as isotope-ratio mass spectrometry (IRMS) [202, 
208]. 
To overcome these disadvantages, leucine was replaced by multiple 2H-labelled 
phenylalanine in most studies. Notably, with multiple 2H-labelled phenylalanine all the 
measurements are possible with standard GC-MS [201, 208]. 
Studies using large amounts of phenylalanine in flooding dose technique do not show a 
stimulation of protein synthesis by the pulse dose [205, 213]. 
Studies have shown that for phenylalanine the curves of enrichments in plasma and muscle 
do not differ significantly [201]. There is a very good agreement between the enrichments in 
the free amino acid pool and the aminoacyl -RNA pool in muscle and liver with FDT using 
phenylalanine [209]. 
2.3.4.2 The pulse doses 
In humans the pulse doses of phenylalanine are between 30-50 mg/kg, [197, 201, 214]. 
Commonly 45 mg/kg (approximately 3g /70 kg) are infused intravenously during 10 min 
interval in from of a 2% phenylalanine solution which contain labelled phenylalanine mixed 
with unlabelled phenylalanine at the desired enrichment [201]. 
2.3.4.3 Sampling 
During and after administration of the tracer, repeated blood samples are taken. The number 
of blood samples are determined by the number of points necessary to draw the enrichment 
curves. Usually blood samples are taken every 5-10 minutes.  
The time for sampling is 90 min [202, 214], in some studies 120 min [215, 216].   
2.3.5 Gas chromatography-mass spectrometry 
The samples contain a huge number of molecules which need to be separated to analyse 
compound(s) of interest. 
Chromatography is doing the separation of the compounds. 
Both gas chromatography (GC) and liquid chromatography are used for isotopically labelled 
compounds.  
Gas chromatography is the elected method for separation of compounds labelled with 2H as 
in liquid chromatography a lot of 2H will be lost by ion exchanges. To facilitate the volatility 
of compounds of interest from the sample a chemical derivatization is performed before 
processing gas chromatography.  
Mass spectrometry (MS): After passing the GC the chemical compounds are vacuum-
aspirated in the mass spectrometer. MS measures the abundance of molecules for selected 




Known mass-to-charge ratios spectra are used to identify the molecules in the analysed 
sample.  
2.3.5.1 Subtraction of the natural background 
The natural background of the isotopes used in tracers must be taken into account for every 
determination and be subtracted from the enrichment of the samples taken after the 
administration of tracer [194]. If the tracer is the m+1 isotope, the subtracted is the value of 
the natural occurrence of m+1 when m+0 is normalized to 100% [194]. 
2.3.5.2 Determination of low levels of enrichment 
GC-MS detect relatively high levels of enrichment as the precision of measurements is 
around 0.5 APE. Higher levels of enrichments of the free amino acid pool (0.5-20 APE) can 
be thus detected without problem by GC-MS. However, the enrichments of protein bound-
isotopic labelled amino acid are much lower (0,002-0.1 APE), and due to that, much difficult 
to be detected and measured by CG-MS [194, 208].  
A modified GC-MS technique has been used successfully to detect low enrichments of 2H5-
phenylalanine (0.002-0.09 APE) [201, 208]. 
The modification implies enzymatic conversion by decarboxylation of 2H5-phenylalanine to 
2H5-phenylethylamine before the derivatization and analysing with GC-MS [208]. The 
measurements done on 2H5-phenylethylamine are significantly augmented in precision by 
reducing the background noise in GC results almost to zero [208]. 
This technique implies the use of calibration curves of phenylethylamine and curves of 
known phenylalanine enrichments [208].  
2.3.6 Calculation of the protein synthesis rates with FDT 
The flooding technique have been used to determine synthesis of hepatic cellular proteins 
[217-219] as well as of export proteins like albumin [214, 220] and fibrinogen [54, 55, 198, 
215].  
CG-MS determinations deliver the two variables which are needed for calculations: 
1) The isotopic enrichment of the precursor in the precursor pool  
2) The enrichment of the precursor incorporated into the protein. 
Two synthesis rates are calculated: the fractional synthesis rates (FSR) and the absolute 
synthesis rate (ASR) 
1) The fractional synthesis rate (FSR) is de novo synthesis of the studied protein, expressed 
as the fraction of the intravascular protein pool synthetized per unit of time.  
The background behind the formula for FSR calculation is the derivative equation for 
incorporation of the labelled precursor into the protein with respect to time [197]: 
 (1) 
Where                                                                                                                                                                   
mB= mass of labelled precursor in protein (tracer)                                                                                
t = time                                                                                                                                                                 
v = absolute rate of incorporation of the amino acid into protein (mass per unit time)                   
eA= isotopic enrichment of the precursor  
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Dividing all over by the total mass of precursor (the protein pool size), derivative formula 
will be: 
  (2) 
Where 
MB = mass of unlabelled amino acid                                                                                                        
mB = mass of labelled precursor in protein                                                                                               
k= the fractional rate of incorporation of the amino acid into protein                                                                     
eA= isotopic enrichment of the precursor 
The assumption is that protein pool size is constant. The other assumption is that the pulse 
dose of precursor does not influence the rate of protein synthesis. Thus, the size of the 
precursor pool can be ignored and the equation for protein synthesis will include only its 
isotopic enrichment [197], equation (2) may be integrated and the equation is: 
    or 
(3) 
Thus, the formula for calculation of the fractional synthesis rate is [197]:  
 (4)   
Where  
k= the fractional synthesis rate                                                                                                                               
eB(o) = enrichment of the precursor incorporated in the protein at time 0                                                   
eB(t) = enrichment of the precursor incorporated in the protein at time t                                                
eAdt = area under the curve for precursor enrichment versus time 
Usually FSR is given as percentage of synthetized protein per day, and equation (4) can be 
written as: 
         [202, 214] 
Where: 
Ep= the increase in enrichment of the precursor into protein                                                                    
A= area under the curve for precursor enrichment versus time (expressed in days). 
Thus, the equation for FSR calculation in FTD is similar to that used in the continuous 
infusion method. 
It was questioned if it is correct to use this formula as FDT do not produce a steady state for 
the free amino acid pool [221] but instead could imply a massive inflow of precursor in the 
synthesis pool from the expanded amino acid pool. However, this assertion neglected the 
assumption that the flooding dose does not influence the rate of protein synthesis, which was 
demonstrated to be true after all [197]. It is assumed as well that proteolysis is minimal under 
the sampling time which is short and can be ignored [197]. Hence, equation (4) is correct. 
2) The absolute synthesis rate (ASR) per day can be calculated by multiplying FSR with the 
total protein mass in the intravascular pool. Usually ASR is given as mg/kg/day [214]. 
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2.3.7 The issue of multiple determinations using FDT 
To investigate protein synthesis in longitudinal studies, sequential measurements are 
required. Assessment of the time that must pass before proceeding a new determination could 
be problematic and, if sufficient time have not passed, the results may be affected by the 
isotopic precursor baseline caused by the first measurement [213]. Repetitive sampling using 
FDT with short time intervals between determinations exploring synthesis of albumin and 
total protein in the liver has shown that this is a real problem and the results are difficult to 
interpret [222]. 
This issue was not settled, and further studies were therefore needed to determine how 
repeated measurements using the flooding dose technique should be made without 





Objectives of the first part of the thesis: 
In patients with liver failure, standard coagulation tests indicate a risk of bleeding but 
clinically in most cases, there is no obvious tendency to bleed related to coagulation. On the 
contrary, there is evidence of increased thrombotic risk. The objective of the first part of the 
thesis was to search in descriptive studies if thromboelastometry can add value to clinical 
assessment in liver failure in patients with chronic liver disease and after major liver 
resections with a loss of liver mass.  
The specific aims of the first part were: 
1. To characterize the coagulation in patients scheduled for liver transplantation. In this group 
of patients, we also investigated the potential of thromboelastometry to be used as a 
prognostic tool in chronic liver disease. 
2. To characterize the coagulation in patients undergoing major liver surgery, in particular if 
there is a role for thromboelastometry in how to understand and handle potential hypo- and 
hypercoagulation. 
 
Objectives of the second part of the thesis: 
Work nr.2 of the first part of our project revealed that following liver resections fibrinogen 
plasma concentrations had different trends postoperatively depending on the resection size. 
The objective of the second part of the thesis was to investigate the fibrinogen synthesis 
following major liver resections.  
The specific aims of the second part were:  
1. To establish and validate a methodology of repetitive determinations of in vivo fibrinogen 
and albumin synthesis. 
2. To study the perioperative de novo synthesis of fibrinogen and albumin in patients 













4 METHODOLOGICAL CONSIDERATIONS  
4.1 STUDIES DESIGN (ALL STUDIES) 
 
Figure 4: Synoptic view on aims, study population and number of subjects (N=total number 
of subjects in the study; n=number of subjects in subgroups; 1 and 2 indicate the subgroup, 
which in study 2 were 1= hemihepatectomy, 2= extended hemihepatectomy, in study 3 - 




Study 1 was a prospective cross-sectional observational study. The patients were studied at 
the time of the final assessment for liver transplantation. The patients were consecutive in an 
effort to obtain a representative sample.  Post hoc the patients were dichotomized in two 
subgroups according to the Child-Pugh and MELD scores to make comparisons. 
Study 2 and 4. Both studies were prospective longitudinal observational studies. The 
participants were studied preoperatively, in study 2 just before the surgery and in study 4 at 
least 2 days before the operation.  Postoperatively the participants in both studies were 
studied on postoperative day 1, and thereafter in study 2 every third postoperative day during 
the hospitalization, while in study 4 on just one more occasion between postoperative days 3 
to 5.   
Study 3 was a prospective longitudinal study with two protocols (Figure 5). Protocol A with 
determinations at two time points with 48 hours' time interval. Simple randomization was 
performed with 5 subjects in each subgroup with cross-over administration of 2H5-
phenylalanine (D5-phenylalanine) or 2H8-phenylalanine (D8-phenylalanine) at the two 
occasions. Protocol B with determinations at three-time points i.e. at 5 hours and 7 days after 
the first determination. D5-phenylalanine was used at occasion 1 and 3, and D8-
phenylalanine at occasion 2. 
 
Figure 5. The study 3 protocols (in rectangles is given which isotope was used for 
determinations) 
Settings 
All participants in all studies were studied at Karolinska University Hospital, Stockholm, 
Sweden. Coagulation and biochemical analyses were performed at the Department of Clinical 
Chemistry while thromboelastometry was performed at the Department of Clinical 
Immunology and Transfusion Medicine at Karolinska Huddinge University Hospital. At the 
analytical laboratory of the ICU metabolism and nutrition research group at Karolinska 
Institutet were performed analyses for protein synthesis including GC-MS and ELISA 




4.2 COAGULATION AND BIOCHEMICAL TESTS (STUDIES 1, 2 AND 4) 
Samples for coagulation tests were collected into citrated vacutainer tubes.  
Standard coagulation and biochemical tests were analysed on automatic devices. Details 
about the reagents and devices which was used for each test are provided in the manuscripts 
of studies 1, 2 and 4. 
The Owren method was used to determine the prothrombin time in all studies. 
The Clauss method was used to determine plasma fibrinogen concentration in all studies. 
Antithrombin, protein C and protein S levels were determined using functional assays. 
ROTEM® analyses were executed on a ROTEM® delta device (Pentapharm GmbH, 
Munich, Germany) following the standard procedure according to the manufacturer’s 
instructions, by specialized stuff trained to perform this analysis.  
In study 4 the coagulation and biochemical tests were collected just before the procedure for 
protein synthesis through the vascular line dedicated for sampling. 
4.3 THE FLOODING DOSE TECHNIQUE (STUDIES 3 AND 4) 
Vascular access for analysis. For protein synthesis determinations, all subjects had two 
vascular lines. One line was used for the administration of the tracer, the other for sampling. 
Tracer administration:  Unlabelled phenylalanine together with 2H5-phenylalanine (or 2H8-
phenylalanine) 99 molar percent excess (MPE) (Apotek Production & Laboratorier AB, 
Kungens Kurva, Sweden) was mixed to a concentration of 20 mg/ml (2g/100 ml saline) at 
different levels of enrichments according to the study protocol. The 2% phenylalanine 
solution was administrated intravenously in a dose of 45 mg/kg as an infusion for 10 min. 
In study 3 we used 2H5-phenylalanine (alternatively 2H8-phenylalanine) 10 MPE for the 
doses with 5 h and 48 h interval, and 20 APE (after seven days). In study 4 we used an 
incremental dose of 2H5-phenylalanine i.e. 5 MPE preoperatively, 10 MPE on POD1 and 30 
MPE on POD 3-5.  
Sampling: Blood samples were taken before the start of the tracer infusion and at 5, 10, 15, 
30, 40, 50, 60, 70, and 90 minutes after.  
The samples were collected into EDTA vacutainer tubes, kept on ice until centrifugation 
which was performed at 2500 x G for 10 min at 4OC, then plasma was transferred in small 
plastic tubes and stored at - 80OC. 
Measurements were performed by biochemists with long experience in the domain. 
Chemical separations are described in study 3. For enrichment measurements was used gas 
chromatography- mass spectrometry. 
Calculation of synthesis rates 
To determine the synthesis rate for the liver export proteins the flooding method has been 
adapted and pays attention to distinguish between the time of the administration of the 
precursor and the time point when presumably begin the secretion of the protein into plasma 






Accordingly, for the calculation of FSR in study 3 and 4 the following formula was used: 
 [214] 
Where  
P2-P1= the increase of enrichment of the precursor incorporated in the protein secreted during 
time points t1 and t2 (which determined the regression line, after enrichment becomes lineal). 
A= area under the curve for precursor enrichment between t1-tS and t2-tS (tS is subtracted from 
the secretion times to select the part of the area under the curve according to the time points 
presumed to agree with the synthesis times).   
The factors 1440 and 100 were used to give FSR as %/24 hours. 
Absolute synthesis rate (ASR) was calculated by multiplying FSR with the quantity of the 
protein in plasma:  
 
Where  
PC = protein concentration 
PV = plasma volume 
W = weight      
For estimation of the plasma volume in studies 3 and 4 we used the anthropometric method, 
specifically the height cubed + body mass formula (Nadler formulas). These formulas give an 
excellent prediction of the blood volume determined by the isotopic method [223].  
The formula for blood volume (BV) calculation according to Nadler [223] is: 
For men:      BV = 0.6041 + 0.3669 H3 + 0.03219 W  
For women: BV = 0.1833 + 0.3561 H3 + 0.03308 W   
Where                                                                                                                                                                   
W= weight in kilograms                                                                                                                                      
H= Height in meters  
A correction factor of 0.91 representing the difference between peripheral body haematocrit 
and average body haematocrit was applied [223].  









4.4 STATISTICS (ALL STUDIES) 
The statistical methods used in different papers are given in Table 1. 
Table 1. The statistical methods used in different studies are marked by grey shading. 
 Study 1 Study 2 Study 3 Study 4 
Mann-Whitney U test     
Wilcoxon’s matched pairs test     
One-way ANOVA     
Mixed effects model analysis     
Friedman’s ANOVA                                
Two-way ANOVA     
Spearman’s correlation     
Pearson’s correlation     
Fisher’s exact test     
Dahlberg’s formula      
ROC curves     
 
Nonparametric analyses were used if the assumption of normality was not confirmed. 
Normality was tested with Shapiro-Wilk test, D’Agostino & Pearson test or Kolmogorov-
Smirnov test.  
For nonparametric data, Mann-Whitney U test was used to compare two independent samples 
while Wilcoxon’s matched pairs test was used to compare two related samples in repeated 
measurements. 
One-way analysis of variance (ANOVA) was used to analyse the differences between means 
in repeated measures within groups. The lack of sphericity was corrected with Geisser-
Greenhouse correction.  Friedman’s ANOVA with Dunn’s post-hoc test was used for non-
parametric data. Two-way ANOVA was used to analyse differences in changes of repeated 
measures between groups. In study 4, a mixed-effects model analysis (in Prism® 8) was 
performed to compare repeated measures data within and between groups which allowed 
maintaining in the analysis of patients with missing values due to random causes.  In study 4 
post hoc multiple comparisons were performed using Tukey’s test. 
Receiver operating characteristic (ROC) curves were used in study 1 to assess the ability of 
the test to distinguish between the subgroups with different mortality risks. For correlations, 
we used the Pearson's method for normally-distributed data. For non-normally-distributed 
variables, the Spearman's method was used. In study 3, Dahlberg’s formula was used to 
calculate, the so-called pool coefficient of variance based on two observations (the 
imprecision of repeated measurements) under conditions assuming no systematic changes 
between the two occasions.  
The accepted significance level (p) was under 0.05. 
Statistical analyses were performed with Prism® 5, 6 or 8 (GraphPad Software Inc. La 





4.5 ETHICS (ALL STUDIES) 
All study protocols were following Helsinki Declaration and were approved by the Regional 
Ethical Committee in Stockholm, Sweden. All the subjects included in our studies received 
verbal and written information about the study protocols and provided written informed 






























5 RESULTS AND DISCUSSIONS     
5.1 STUDIES 1 AND 2 (AND PARTLY 4)  
In our studies we intended to characterize the patients with hepatic insufficiency also from the 
perspective of a viscoelastic test, which, we hypothesized, could have add value to the 
clinical assessment. We chose ROTEM® because this was the standard viscoelastic test in our 
institution. ROTEM® had been used during liver transplantations as a point of care testing of 
coagulation, with good results, especially reducing transfusion of blood and blood products. 
Nevertheless, a full thromboelastometric characterization of coagulation in the population 
accepted for liver transplantation or following major liver resections was not available at the 
time when we began our project. 
5.1.1 The ROTEM®’s role in assessment of prognosis in chronic liver 
disease (study 1) 
There were only a few publications regarding the viscoelastic test assessing of coagulability 
in patients with liver cirrhosis [49, 115, 224] and just one which regarded the mortality risk 
assessment by thromboelastometry [115]. Based on a good correlation of severity scoring 
systems Child-Pugh and MELD with some ROTEM® parameters, Tripodi et al. suggested 
that thromboelastometry could be applied not only to assess coagulopathy and the risk for 
bleeding but also for investigating the severity of liver cirrhosis. The most interesting 
parameter to be considered for prognosis proposes was MCF and to a lesser extent CFT 
[115]. 
Tripodi’s report was promising considering that PT-INR, as the only coagulation parameter 
included in the scoring systems Child-Pugh and MELD, was questioned as potentially 
misleading the liver cirrhosis severity assessment and thus the priority for liver 
transplantation [73, 124, 126].  
However, the study was not sufficient to conclude this issue mainly because of the low 
number of patients in end-stage liver disease (only 12% of the included patients were in 
Child-Pugh C stage), and because of narrow etiological spectrum consisting in hepatitis liver 
cirrhosis (68 %) and alcoholic liver cirrhosis (17%) [115].   
In study 1 we tested the hypothesis that ROTEM® can discriminate the degree of severity in 
stable chronic liver disease. A secondary aim was to assess ROTEM®'s ability to predict 
bleeding or thrombosis.  
For this purpose, we enrolled consecutive patients undergoing an evaluation for liver 
transplantation.  We dichotomized the patients into two groups to compare them. One group 
consisted of severe liver cirrhosis patients in Child-Pugh class C. Lesser sick patients in 
Child-Pugh A and B stages formed in the other group. We dichotomize as well according to 
MELD score at a cut off 17.  These two groups, according to Child-Pugh and MELD score, 
had almost the same size and were reasonably sized to give a statistical power of 0.8.  
Statistical comparisons showed no differences in ROTEM® parameters between these groups 
of patients in earlier stages of liver disease compared with late stages (Figure 6 on p.43). 
ROC curves were produced to assess the performance of ROTEM® parameters to predict 
Child-Pugh or MELD scores. For all ROTEM® parameters, the area under the curves (AUC) 
of corresponding ROC curves indicated that this test could not discern if patients were on a 
lower level of gravity or in end-stage liver disease (for MCF see Figure 7 on p.44) (see also 





Figure 6. The ROTEM® parameters in patients (n=40) included in study 1. The horizontal 
line represents the median value.  Comparations were made by Students t-test or Mann-
Whitney U test as appropriate and the p value is given in the upper right corner.(The blank 
area=hypocaoagulability,the intense shaded area= hypercoagulability)  
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Figure 7. Receiver operating characteristic (ROC) curves of MCF concerning the subgroups 
of patients according to Child-Pugh and MELD scores in study 1.  
 
We performed a post hoc regression analysis for MCF against the MELD score, which 
revealed extremely low coefficients of determination r squared (r2) (Figure 8, panels A-C). 
MCF (INTEM, EXTEM or FIBTEM) explained only 5-8% of MELD variance.  
Interestingly, advanced stages of liver disease had other relationships with ROTEM® 
parameters compared to early stages. Hence, this post hoc analysis disclosed that in the 
subgroup of the less sick patients (MELD ≤ 16) there was a good correlation of the scoring 
systems with the parameters CFT and MCF, explaining between 31-43% of MELD variance, 
while in the subgroups of sicker patients the correlation was almost 0 given an r2 coefficient 
of .01(see Figure 8, panels D-F). The same pattern was observed in Child-Pugh scoring 
(Figure 9 on p.45). Thus, when the patients in the advanced stages are added to the group, the 
correlation decrease and became insignificant for the entire cohort for most of the ROTEM® 
parameters. Hence, what Tripodi et al. alleged might be correct for patients within less 
advanced stages of liver disease but should not be a rule for the entire spectrum of severity, 
especially if a significant number of patients with advanced liver disease are included. 
Figure 8. Regression analysis MCF vs. MELD score in patients with chronic liver disease 
included in study 1, for all patients (n=40) (panels A-C) and for subgroups MELD ≤16 







Figure 9. Regression analysis MCF vs. Child-Pugh score A+B (n=22) and C (n=18) in 
patients with chronic liver disease included in study 1. 
 
MCF-FIBTEM correlation with Child-Pugh score (and to some extent and a lower 
significance with MELD score) seeks an explanation which we don’t have now. This 
correlation is lacking in other cohorts with proportionally fewer patients in Child-Pugh C, 
although the prevalence of lower values of MCF-FIBTEM is significantly higher in patients 
with advanced chronic liver disease [48]. A possible explanation could be an increasingly 
dysfunctional fibrinogen molecule [60, 225] in end-stage liver disease that might have an 
impact on MCF FIBTEM. In support of this hypothesis is that in a previous study MCF 
FIBTEM could not differentiate healthy subjects from a cohort of stabile cirrhotics 
predominantly in stage Child-Pugh A and B [115].  
Our findings in study 1 let us to conclude that we found no use for ROTEM® parameters for 
prognosis purposes in an unselected group of patients with stable chronic liver disease, 
similar to our sample.   
Our finding disagrees with the suggestion that, as a rule, thromboelastometry, in particular, 
MCF, could be used to assess disease severity [115, 116]. 
Our conclusion that thromboelastometry has a limited role in predicting outcome in stable 
liver cirrhosis was an original finding. Although the external validity was limited by the case-
mix for liver transplantation at our centre, the characteristics of the cohort investigated was 
similar to other European liver transplantation centres [226]. Another more recently study 
investigating the same issues with thromboelastography came out with a similar conclusion 
[227]. The results of a very recent study using thromboelastometry on patients with stable 
liver cirrhosis confirmed our conclusion [228] 
A different situation could be in decompensated chronic liver failure. A recent study reported 
the parameter CT EXTEM > 80 s, at admission in the ICU, as a predictor of 28-days 
mortality in patients with acute-on-chronic liver failure [122]. 
5.1.2 Coagulation after major liver surgery (study 2) 
We explored in our study 2 the hypothesis that viscoelastic tests can add value to the 
evaluation of coagulation status and risk assessment regarding bleeding and thrombosis 
following major liver resections. 
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We, as others before us [118, 134], showed in study 2 that during the first postoperative days, 
there is a decrease not only in pro-coagulant factors, which is reflected by PT-INR and 
fibrinogen plasma levels but also in anti-coagulant proteins such as AT and protein C. 
To characterize the coagulation process, we analysed our samples with thromboelastometry, 
which showed the patients in coagulation re-balance throughout the entire observed 
postoperative period. In some individuals’ signs of hypercoagulability was observed on 
postoperative days 4 and 7 (Figure 13 on p.51). 
5.1.3 The ROTEM®’s role in assessment of coagulations balance in patients 
with live failure (studies 1, 2 and 4) 
The status of coagulation (the coagulation balance in particular), when assessed by 
viscoelastic tests, requires an interpretation of all parameters together. Individual ROTEM® 
parameters could be used to assess the balance within the segment of haemostasis that is 
reflected by each of them.   
The CT parameter reflects the coagulation factors and the anticoagulants, while the MCF 
gives information mainly on the fibrinogen-platelets functionality. CFT is in between CT and 
MCF and related to thrombin generation as well. 
Overall the results of study 1 showed normo- and hypocoagulability on ROTEM® for the 
entire cohort (Figure 6 on p.43).  
CT was exceedingly normal, which indicated a rebalanced secondary haemostasis in any 
stage of liver failure, even in the end stages.  
Regarding CFT and MCF in INTEM and EXTEM, they showed balanced coagulation only in 
50 % of the patients with liver cirrhosis and hypocoagulability for the rest of the group 
(Figure 6 on p.43). 
Other studies report similar results in cirrhotic patients although with different proportions in 
balanced coagulation according to different ROTEM® parameters which could be due to 
differences in the etiological and severity case-mix of the samples [49, 115, 116]. 
Studies using TEG®  show the same pattern although more balanced than ROTEM® based 
studies [114] while in patients during liver transplantation TEG®  provides signs such as high 
G values (a clot firmness parameter derived from the maximum amplitude MA which 
correspond to MCF in ROTEM®) and short R times (which correspond to CT in ROTEM®), 
suggesting hypercoagulability in some but not all patients with cholestasis pathologies like 
PBS and PSC [117]. However, we could not see hypercoagulability in our study 1 cohort also 
including patients with these conditions.   
In patients with liver dysfunction after major liver resections (study 2), we could demonstrate 
a different kind of rebalanced coagulation compared to chronic liver failure, with a majority 
of patients remaining inside the normal ranges in all ROTEM® parameters during the entire 
postoperative period (Figure 10 on p.47).  
The results of study 2 showed that despite significant coagulation abnormalities in pro- and 
anticoagulant pathways as reflected by standard coagulation tests, ROTEM® indicated 
balanced coagulation with a stable trend postoperatively. Hypocoagulability on ROTEM® 
was exceptional and associated with complications such as grave liver failure or subcapsular 
hematoma of the liver.  In some patients, hypercoagulability on postoperative day 4 and 7 





Figure 10. The ROTEM® parameters from studies 1 and 2 in INTEM and EXTEM. The 
horizontal line represents the median value. The blank area=hypocaoagulability, the intense 
shaded area= hypercoagulability. Comparisons were made by Kruskal-Wallis test with and 
the p values are given in the upper right corner. * denotes Dunn’s post-hoc test statistical 
significance p < 0.05. (CDL= chronic liver disease in study 1; D1, D4= postoperative day 1 
and 4 in study 2). 
The coagulation re-balance following major liver resections, reflected by a very stable CT, 
may come by concomitant decrease in procoagulant factors (mirrored by the PT-INR) and the 
natural anticoagulant factors AT and protein C. At the same time, a firm clot is assured by the 
fibrinogen-platelets functionality. This approach in thinking grounded the concept of 
rebalanced coagulation in liver cirrhosis [85], and we showed in study 2 using ROTEM® 
that a similar situation is present during the liver dysfunction following major liver resections. 
We noted as well that a tendency towards hypercoagulability existed on postoperative day 4 
and onwards, more expressed after hemihepatectomy.  
The main conclusion in study 2, that coagulation might be re-balanced following major liver 
resection similarly to chronic liver disease is original. We also showed that because of 
rebalancing, the risks for bleeding in these patients are small, even though standard 
coagulation tests could indicate such a risk. 
Our results were in agreement with the results published by De Pietri et al., who used TEG® 
[118] with the exception that they didn't report signs of hypercoagulability. To be remarked 
that at that time, TEG® was not equipped with functional fibrinogen analysis. 
A while after study 2, a study was published using ROTEM® on patients undergoing major 
liver resections, which have similar results and conclusions [147]. 
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In study 4 we noted no perioperative differences in ROTEM® parameters CT, CFT and MCF 
between patients undergoing major liver surgery and pancreatectomies (see additional file 2 
in study 4). This confirmed the findings in study 2 and showed that after the loss of a 
considerable liver mass by surgical resection the re-balancing of coagulation occurred in 
comparable ranges with the pancreatectomy control group with intact liver. 
In studies 1, 2 and 4 the alpha (α) angle had a good correlation with CFT and similar results 
in the statistical analyses as CFT (for this reason the alpha (α) angle data was not included in 
this paper). The ROTEM® clot lysis parameter ML didn’t have any denoting relation with 
the studied outcomes in studies 1, 2 and 4 and due to this was not included in this paper. 
5.1.4 The fibrinogen (and platelets) function reflected by ROTEM® in liver 
failure (studies 1, 2 and 4) 
The relationships between fibrinogen plasma levels and ROTEM® parameters are described 
in study 1, 2 and 4. Essential, the action of fibrinogen on ROTEM® parameters regarding 
the clot firmness, should always be combined with the effect of the platelets on these 
parameters. Considering subtracting platelets contribution, MCF FIBTEM reveals the 
fibrinogen action only.  
Fibrinogen has a vital role in balancing the coagulation disorders [62, 229]. 
Both in study 1 and studies 2 and 4 the patients had balanced coagulation according to 
MCF-FIBTEM.  
80% of the patients included in study 1 had an MCF FIBTEM inside the normal ranges, 
while only 57 % of the patients had normal plasma fibrinogen (Figure 11). Thus, many 
patients with plasma fibrinogen under normal range may still have a normal MCF FIBTEM 
which, in itself, can be considered a measure of balanced coagulation in the fibrinogen 
domain. This indicates the fact that fibrinogen plasma levels alone cannot give full 
information about how balanced fibrin-specific clot formation is, and a viscoelastic test 
should confirm this. 
 
Figure 11. MCF FIBTEM and plasma fibrinogen from studies 1 and 2.  The horizontal line 
represents the median value. The blank area=hypocaoagulability, the intense shaded area= 
hypercoagulability. Comparisons were made by Kruskal-Wallis test with and the p values are 
given in the upper right corner. * denotes Dunn’s post-hoc test statistical significance p < 




The absence of correlation of MCF (INTEM and EXTEM) with scoring systems in study 1 
most likely relies on fibrinogen and platelets influence on this parameter. Patients in end-
stage liver disease had low as well as high plasma levels of fibrinogen to the same extent as 
patients in earlier stages of liver disease. This was a piece of essential information that helped 
to clarify our findings regarding the relation between ROTEM® and scoring systems in the 
studied sample of the population. 
In study 1 and study 2, as expected, there were correlations of fibrinogen concentration in 
plasma with CFT and MCF, but not with CT.   
For studies 1, 2 and 4 the fibrinogen plasma concentrations had similar correlation 
coefficients with MCF EXTEM/INTEM as with MCF-FIBTEM (Table 2 on p 54). 
According to Fisher r-to-z transformation there was no significant difference between the 
correlation coefficients either within or between the groups.  
Table2. Fibrinogen vs. MCF, Spearman correlation coefficients (rs) with corresponding p 
values (CDL= chronic liver disease, D1/D4/D3-5= postoperative day 1/day4/day3-5) 
Group/subgroup MCF INTEM MCF EXTEM MCF FIBTEM 































An interesting finding in a post hoc analysis was that in chronic liver disease, platelets count 
correlates with MCF –FIBTEM (study 1), which is not the case for non-cirrhotic patients 
after major liver resections (study2) (Figure 12 on page 50). The questions which emerge 
from this observation is either if cirrhotic platelets are resistant to Cytochalazin-D or if 
cirrhotic plasma could affect the results giving a better coagulability and cloth firmness in 
FIBTEM samples inhibited with Cytochalazin-D. If this finding is confirmed by other 
studies, it is a reason to rethink how MCF FIBTEM should be interpreted in patients with 
liver cirrhosis and eventually adjust the method. 
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Figure 12. Spearman correlation coefficients (r) of platelets count with MCF-FIBTEM for 
study 1(n=40) and study 2 (n=16) cohorts (CDL= chronic liver disease, D1/D4= 
postoperative day 1/day4) (r and p values are given in the parenthesis for each analysis) 
 
5.1.5 The ROTEM®’s role in predicting bleeding and thrombosis in liver 
failure (studies 1and 2) 
5.1.5.1 The bleeding risk assessed by ROTEM® in liver failure 
There is no evidence that viscoelastic tests (VETs) can be used to predict bleeding in patients 
with liver cirrhosis [230], and our study 1 did not clarify the matter. The material was 
insufficient in size to be conclusive, and it was therefore hypothesis-generating only. Here 
ROTEM® analyses were made at a time distance from the liver transplantation and had no 
predictive value for bleeding. The possible predictive value for VETs on peroperative 
bleeding, when taken immediately before the procedure, remains to be elucidated [230]. 
The main factor for bleedings in liver cirrhosis is hypertension in the portal system and not 
coagulation disorders as the most stabile patients are in a rebalanced haemostasis [62]. Our 
study 1 demonstrated that 92 % of patients with stable liver disease had a balanced 
coagulation status according to CT, but only 50% of them according to MCF. However, we 
found no association between indirect signs of portal hypertension and bleedings on the 
waiting list period either.  
In study 2, the patients were generally balanced according to ROTEM®, and there were no 
postoperative bleedings of clinical importance. Hence, we could not draw any conclusions 
regarding the predictability of postoperative bleeding.  
5.1.5.2 Predictability of thrombosis based on ROTEM® 
Lately there is an increasing focus upon the tendency to venous thrombosis [95] and 
hypercoagulability, especially in the end stages of liver disease [74, 78, 231]. It is reported 
that the thrombin generation tests in the presence of thrombomodulin increase with liver 
disease progression to the end stages [49]. It is actually suggested that, rather than insufficient 
haemostasis, an imbalance towards hypercoagulability is more likely to occur in end-stage 
liver disease [78, 79].  
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In our study 1, no single patient presented signs of hypercoagulability on ROTEM®, defined 
as being out of normal range in more than 1 ROTEM® parameter, either in the early or in the 
end stages of liver disease in our cohort of patients. It could be speculated that in advanced 
stages of liver disease, exacerbated thrombin generation could be drawn back by a defected, 
slower polymerization due to dysfunctional fibrinogen [60, 225]. Thus, the thrombogenesis 
will not deviate to hypercoagulability. Another possible explanation is that ROTEM® cannot 
reveal hypercoagulability in liver cirrhosis because the normal ranges are not adapted to this 
rebalanced haemostasis.  Other ROTEM® based studies failed to show hypercoagulability in 
patients with chronic liver failure as well [49, 116].  
In study 1, the patients with portal vein thrombosis at the time of sampling had no signs of 
hypercoagulability on ROTEM®. However, the mechanism of thrombosis is often 
multifactorial, and Virchow’s triad also point out portal flow disturbances and the 
endothelium as pathogenic factors for portal thrombosis. 
In study 2, a tendency towards hypercoagulability could be noted on postoperative day 4 and 
postoperative day 7 on specific ROTEM® parameters, especially on CT EXTEM and MCF 
FIBTEM (Figure 13).   
The rapid recovery of procoagulant factors reflected by PT-INR and fibrinogen plasma levels 
compared to anticoagulation proteins AT and protein C, which remained at lower levels a 
much longer period, could explain the signs of hypercoagulability which are more expressed 
in patients with hemihepatectomy then after enlarged hemihepatectomy.  
The two patients included in the study who developed VTE, both had ROTEM® parameters 
that indicated the tendency to hypercoagulability and one of them undoubtedly had 
hypercoagulability signs on CT and CFT EXTEM and MCF FIBTEM days before the lung 
emboli occurred (Figure 13). The MCF FIBTEM trend in both patients showed a rapid 
recovery on postoperative day 4 with a sharper angle than the median. These cases suggest 
that ROTEM® could indicate the risk for thrombosis after major liver resections but are far 
from sufficient to set limits of risks.  
 
 
Figure 13. ROTEM® parameters in patients (n=16) included in study 2. The normal range is 
indicated by dotted green lines. Median value is presented as a dotted red line for all patients. 
The two patients with pulmonary embolism are shown in bold blue and green line which are 




5.1.5.3 The need for defining ROTEM® risk ranges for patients with chronic liver 
disease 
Preoperative ROTEM® parameters A10 and CFT are suggested as predictors of 
postoperative thrombotic complications after major non-cardiac surgery [179]. May this be 
extrapolated to major liver surgery or liver cirrhosis? 
Studies with ROTEM®, including our study 1 failed to show hypercoagulability in cirrhotic 
patients. Why? Was there a case-mix problem or were the "normal ranges "for liver failure 
inappropriate? Or simply, there was no hypercoagulability? ROTEM® analysis could raise 
this supposition although it contradicts the broad consensus that patients with stabile liver 
cirrhosis are normo- or hypercoagulable [67].  
Half of our cirrhotic patients included in study 1 had a normal CT, but CFT and MCF were 
in the hypocoagulation area. How should this be interpreted in terms of predictions?  
It seems that with ROTEM®, we are stuck in the same dilemma that we had with PT-INR 
which is more or less useless in predicting bleeding in liver cirrhosis. ROTEM® was not 
shown to be of much help for either bleeding or thrombosis predictions in chronic liver 
failure in our hands and in our patient case-mix. So, the utility of viscoelastic tests may be 
limited to the status of point-of-care tests during surgery.  
Reference ranges specific for patients with liver insufficiency may surpass this limitation. 
However, defining what the valid group of reference subjects is may be difficult due to 
variability between patients considering the aetiology and stage of the liver disease. 
The use of ROTEM® has been very helpful in surgical procedures associated with major 
bleedings, like liver transplantation, trauma, and cardiac surgery. When transfusion 
algorithms were directed by conventional coagulations tests like PT-INR, there was a 
tendency towards over-transfusion. Currently there are algorithms for treatment based on 
ROTEM® with cut-off values which are quite similar for liver transplantation (p.265 in [35]) 
and severe bleeding in trauma, and cardiac surgery [35, 177, 187]. Considering modifications 
in coagulation pathways, which subsequently rebalance the coagulation system on lower 
levels of pro- and anticoagulant factors, it is unlikely that liver cirrhosis patients are similar to 
the non-cirrhotic population in terms of risks assessed by ROTEM® parameters. Recently 
published algorithms’ set lower thresholds on A5 for administrating of pro-coagulant therapy 
for bleeding under liver transplantation compared to other types of operations, however there 
are minimal differences in the CT thresholds compared to non-cirrhotic bleedings [176].  
 
5.2 STUDIES 3 AND 4 (AND PARTLY 2) 
5.2.1 Methodological clarifications concerning the FDT methodology for 
multiple determinations of fibrinogen and albumin synthesis in 
humans (study 3) 
In study 2 we found that the pattern of fibrinogen concentration in plasma postoperatively 
was related to the size of liver resection. Therefore, we considered a study where this pattern 
would be explored combined with measurements of de novo fibrinogen synthesis rates. The 
working group was experienced in quantitative measurements of another export protein from 
the liver, albumin. Therefore, the same methodology was considered also for synthesis rates 
of fibrinogen. Before launching a patient study a few methodological issues were to be 
solved, and also our laboratory needed a run-in study for the new analysis of fibrinogen 
synthesis rate. The main methodologic question was, how frequent multiple assessments of 
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fibrinogen synthesis rate were possible with maintained accuracy. This may be solved by an 
increase in the tracer to tracee ratio in a second measurement, or by introducing a different 
tracer in a second measurement. To sort this out we launched a study in healthy volunteers. In 
the protocol of study 3 the flooding dose technique for determination of de novo fractional 
and absolute synthesis rates (FSR and ASR) of fibrinogen and albumin with repeated 
measurements taken at different time intervals using two isotopic traces. We analysed the 
differences in variance between determinations. In this study, we used the stable isotope 2H5-
phenylalanine (D5-phenylalanine), which is standard in this method [198]. We also 
investigated the possibility of introducing a second isotopic label, 2H6-phenylalanine (D8-
phenylalanine), trying to shorten the interval between measurements (Figure 5 on p. 37). 
This was an original idea and part of the hypothesis in this study. 
The complete dataset and the statistical comparisons are provided in the published study 3.  
The study showed that an interval of at least 48 hours between measurements was appropriate 
when the flooding dose technique was used in longitudinal studies. In addition, the results 
showed that 5 hours’ time interval was to short and gave less accurate results even when two 
different isotopic labels for phenylalanine are used. Hence, the results from study 3 gave 
guidance regarding the time intervals between measurements in longitudinal studies of liver 
export proteins. Additionally, the study demonstrated the non-inferiority of the tracer D8-
phenylalanine compared to D5-phenylalanine in the flooding dose technique. However, 
introducing a second isotopic label did not allow shortening the time intervals to 5 hours 
between measurements.  
5.2.1.1 Fibrinogen and albumin synthesis rates  
A few studies in the literature report synthesis rates of fibrinogen in healthy persons. Due to 
the low number of participants in the studies, it is improper to define a normal range for 
fibrinogen or albumin synthesis rates. However, comparisons between the reported synthesis 
rates values can be made if the determinations are performed with the same technique [54, 55, 
216, 232]. 
Figure 14. Fractional synthesis rates of fibrinogen and albumin in healthy persons included 
in study 3. For comparison, results are given from two previous studies published by Caso et 
al. [55, 233]. (D5, D8= D5-, D8-phenylalanine. In red are depicted the median values). 
In study 3, FSRs for fibrinogen in protocol A were comparable with what is reported 
previously, a bit higher in the protocol B [55], while for albumin FSRs were higher than what 
is reported in a previous study [233] (see Figure 14). These differences may be related to the 
administration of a standardized meal including proteins in our study protocol before the 
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measurements, as the synthesis rates of fibrinogen and albumin increase following feeding, 
especially with meals with high protein content [55, 233, 234].  In contrast, the protocols of 
Caso et al. were performed in the post-absorptive state [55, 233]. 
Study 3 emphasized a well-known fact, that standardization during sampling is very 
important to reduce variability. The difference between the coefficients of variation regarding 
determinations with 7 days' time interval was higher for fibrinogen synthesis than for albumin 
synthesis which may be related to physiologic intercurrent inflammatory factors rather than to 
protocol or analytical causes. 
5.2.2 The pattern of fibrinogen synthesis and fibrinogen plasma 
concentration postoperatively in major liver surgery (study 4) 
In study 4 we determined the de novo synthesis rates for fibrinogen and albumin following 
hepatectomies and pancreatectomies (as controls). The driving force behind this research was 
the results of study 2 showing that the size of the remnant liver may be a factor influencing 
the postoperative alterations in plasma fibrinogen concentrations [235].    
The study 4 results indicated that after hemihepatectomies, the liver synthetic function 
concerning fibrinogen was remarkable good. Fibrinogen synthesis on postoperative day 1 was 
roughly 2.5 to 3.5 times higher than preoperatively. As compared to the pancreatectomy 
group, with no loss of liver tissue, the variability of the increase in fibrinogen synthesis rate in 
hepatectomies was much greater. On postoperative days 3-5 a reversal was observed in both 
types of surgery and the synthesis returned towards lower levels, still higher than the 
preoperative ones, particularly following liver surgery (Figure 15).  
 
Figure 15. Fibrinogen synthesis rates and plasma concentrations given as medians, in 
patients undergoing pancreas and liver surgery (study 4), preoperatively (Day 0) and 
postoperatively (Day 1, and Day3-5). Statistical analyses are provided in the study 4 
manuscript. 
5.2.3 Plasma fibrinogen concentration, a reflection of the dynamic balance 
synthesis-catabolism-extravasation (study 4) 
Plasma concentration of a protein does not reflect only the synthesis but also usage, 
degradation and trans-capillary migration of the protein [214]. Hence, the levels of plasma 
fibrinogen can only be explained by all these factors combined.  
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Despite the notable increase in fibrinogen synthesis on postoperative day 1, the plasma 
concentrations did not respond accordingly, remaining unchanged after pancreatectomy and 
decreasing marginally after hepatectomies, thus suggesting that important amounts of de 
novo synthetized fibrinogen was used within a relatively short time interval.  
Following liver surgery, evidences indicate that the highest level of coagulation activation 
and thus fibrinogen utilization is at the end of surgery [143]. According to the levels of 
coagulation markers TAT and fpB, fibrin formation was not massively increased on 
postoperative day 1. However, following liver surgery, a higher level of ongoing fibrin 
formation even on postoperative day 1 was indicated by the soluble fibrin concentrations. 
Presumably the rise of plasma fibrinogen concentration, which most likely commenced early 
following pancreas and liver surgery [118, 147] was slowed by ongoing utilization especially 
following liver surgery. 
It is possible that fibrinogen plasma concentration was not solely dependent on production 
and utilization in fibrin formation.  Alternative catabolic pathways for fibrinogen may also be 
involved in fibrinogen disappearance from plasma to a large extent [50, 236].  
It is not known if fibrinogen transcapillary transit occurs in inflammatory conditions. 
Extrapolating the behaviour of albumin to fibrinogen, the passage may accelerate, which 
would then have consequences on plasma fibrinogen concentrations. However, size of 
fibrinogen molecule is very different from albumin, more than 5 times larger. 
In study 4 we found no correlation between fibrinogen plasma concentrations (or changes in 
concentrations) and the synthesis rate of fibrinogen postoperatively following major 
abdominal surgery, with or without loss of liver tissue.  This lack of correlation may result 
from the plasma concentration being controlled not only by de novo synthesis, but also by its 
usage in the coagulation process, degradation by alternative catabolic pathways and possible 
increased extravasation.  
An issue concerning liver cirrhosis is worth mentioning here. Fibrinogen catabolism in liver 
cirrhosis, measured with techniques using fibrinogen labelled with radioactive iodine, is 
reported to be increased by 30% compared to healthy subjects [237]. However, coagulation 
markers do not indicate an exacerbation of coagulation, and thrombin generation is reported 
to be normal in stabile cirrhosis [76, 238]. Although there are evidences of slightly increased 
fibrinogenolysis in liver cirrhosis [239], this cannot explain such a large increase in 
fibrinogen utilization.  
5.2.4 The regulation of the fibrinogen synthesis (study 4) 
The fibrinogen plasma concentration, reflecting the balance synthesis-utilization-
extravasation, is as it seems regulated and maintained inside a range which allows for a 
normal coagulation. The mechanism which regulates the plasma fibrinogen levels is not 
elucidated. It is not known if fibrinogen concentration itself has a role in this mechanism by 
modulating its own synthesis.  
5.2.4.1 The fibrinogen synthesis stimulation 
As indicated by rat and human cell lines studies, IL 6 is the main inducer of fibrinogen 
synthesis [43, 56, 240].  
Following major abdominal surgery, the peak for plasma IL-6 occurs early (12-24 hours) 
postoperatively, and its concentration correlates with the magnitude and length of the 
operation, open liver resections and pancreatectomies having among the highest increases 
of IL6 compared to the preoperative values [241-243]. Thereafter the plasma levels of IL-6 
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decrease quickly towards normal levels at 72 hours postoperatively if no complications 
occur [242, 243]. This IL-6 plasma levels pattern follows exactly the time pattern of 
fibrinogen synthesis described in study 4. 
5.2.4.2 The connection to the coagulation balance 
Thromboelastometry showed balanced coagulation postoperatively after both pancreas and 
liver surgery. Maintaining the coagulation in normal ranges is a complex process and was 
most likely acquired by different mechanisms following liver resections compared to 
pancreas surgery. However, fibrinogen is most likely a key point in this process.   
We hypothesized in study 4 that after major abdominal surgery the fibrinogen synthesis was 
modulated to counterbalance the fibrinogen disappearance from the plasma pool and attain 
plasma concentrations with which the coagulation system was accustomed (these were the 
preoperative values), and it assured an essential substrate for coagulation. Also following 
hepatectomies this goal was achieved despite the loss of liver mass.  
Our reasoning advanced thus the hypothesis that inputs coming from the coagulation system 
may influence the fibrinogen synthesis. So hypothetically there may be a feedback 
mechanism to control the fibrinogen synthesis. Too much fibrinogen synthesis may cause a 
hypercoagulability, an insufficient synthesis will put the patient at risk for bleeding. 
May this hypothesis be extended to the patients with chronic liver disease? The only study 
investigating the fibrinogen and albumin synthesis in liver failure is a case-series of patients 
with liver cirrhosis caused by hepatitis, published 1996 by Ballmer et al. [198].  
In Ballmer’s study, the liver function is measured by galactose elimination capacity and the 
aminopyrin breath test which doesn’t correlate with fibrinogen synthesis, but it does 
correlate with albumin synthesis rates which are lower in advanced stages of liver disease. 
The lack of correlation may be caused by the fact that fibrinogen as an acute phase protein 
has a larger range of variance compared to albumin.   
In Ballmer’s study the patients in Child-Pugh score (CPS) A have a plasma fibrinogen 
median of 2.2 g/L and in CPS B 1.1 g/L while in CPS C of 1.5 g/L. In these patients’ 
fibrinogens FSR/ASR is lowest in CPS B, while synthesis rates in CPS C are comparable 
with CPS A which, although lower, are in the proximity of the reported values in healthy 
population.  
Even though the concept of rebalance coagulation didn’t exist at that time, Balmer et al 
intuited this and stated that fibrinogen is “vital" for coagulation to work properly, and because 
of this the synthesis may be preserved even in advance stages of liver cirrhosis [198]. So, in 
advanced stages of chronic insufficiency the liver may have the capacity to modulate 
upwards the synthesis rates in order to achieve the plasmatic goal at which the coagulation 
system is rebalanced, which for the Ballmer’s study advanced liver cirrhosis subgroup was 
around 1.5 g/L. However, Ballmer’s study is limited by a low number of patients especially 
in CPS C stage.   
5.2.5 Fibrinogen and albumin in the assessment of the intrinsic synthetic 
function of the remnant liver (study 4) 
Our data from study 2 suggested that the critical liver mass which could not assure enough 
fibrinogen synthesis may be the remnant liver after extended right hemi-hepatectomy. It is 
very likely that a remnant liver of less than 20 % of the initial liver volume cannot avoid a 
severe hepatic insufficiency [244]. After performing study 4 and understanding the 
potentiality of fibrinogen synthesis in the liver, we can presume that an insufficiency of 
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fibrinogen synthesis can only occur in severe post-hepatectomy liver failure with an 
inadequate parenchymal volume and/or functionality. Conversely, a slowness or inability in 
restoring fibrinogen plasma concentrations on postoperative days 3-5 at reasonable levels 
might be a marker of risk for severe post-hepatectomy liver insufficiency.  
In study 4 the albumin plasma concentrations decreased significantly on postoperative day 1 
both after pancreatectomies and hepatectomies and remained low, which is the usual 
postoperative pattern following major abdominal surgery [245, 246] (Figure 16). It has 
already been shown that the postoperative drop of plasma albumin is mainly due to an 
increased albumin extravasation with redistribution to the extravascular space [247]. 
Following liver surgery, the albumin synthesis rates remained unchanged, while following 
pancreas surgery on postoperative day 1 they were de facto about 50% higher on 
postoperative day 1. Considering the important loss of liver tissue following hepatectomies, 
we may assume that the synthesis of albumin was increased per gram of tissue in the remnant 
liver too.  
 
Figure 16. Albumin synthesis rates and plasma concentrations given as medians, in patients 
undergoing pancreas and liver surgery (study 4), preoperatively (day 0) and postoperatively 
(day 1, and day3-5). Statistical analyses are provided in the study 4 manuscript. 
 
Completion of the concept Posthepatectomy Liver Failure (PHLF) regarding synthesis 
function of the liver mirrored by PT-INR 
Hyperbilirubinemia and increased PT-INR during the first 5 postoperative days are signs of 
liver dysfunction [132, 248, 249]. However, these two signs are transitory in most patients 
and the so called “50-50 criteria“ definition of post-hepatectomy liver failure (PHLF) does 
not include the first 5 postoperative days [132]. 
Aiming at a more precise statement, a consensus conference defined PHLF as inability of 
liver to “maintain its synthetic, excretory and detoxifying function” consistent with plasma 
INR and bilirubin [250].  
In study 4 we found no correlation between PT-INR or bilirubin and the synthesis capacity in 
the liver for albumin and fibrinogen.  Although PT-INR on postoperative day 1 increased 
above the normal values, the de novo synthesis of fibrinogen was substantially higher than 
preoperatively, and the albumin synthesis rates were not decreased. 
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Our findings indicate that the definition for PHLF may not be fulfilled considering that PT-
INR cannot mirror the global synthetic capacity of the liver. PT-INR, although dependent on 
coagulation factors synthetized in the liver, is validated only to monitor the treatment with 
vitamin K antagonists and can only evaluate the functionality of the extrinsic pathway of 
haemostasis [86]. Yet, PT-INR is perceived as reflecting the synthetic function of the liver. 





6 LIMITATIONS  
In studies 1, 2 and 4 we did not perform sophisticated coagulation tests to explore thrombin 
generation and fibrinolysis.  
It is debatable if viscoelastic tests can entirely estimate the balance of coagulation especially 
because these tests cannot measure the contribution of vWF and protein C.  In studies 1, 2 
and 4 we used a standard thromboelastometry, i.e. protein C was not activated during the test. 
The relatively low number of patients in study 1 didn't give us the possibility to conclude 
over the risk of bleeding and thrombosis. 
In studies 1, 2 and 4 we did not screen systematically with imagistic techniques for deep vein 
thrombosis and pulmonary embolism. 
In study 2 we did not evaluate the effect of synthetic colloid administrated perioperatively on 
the ROTEM® parameters. 
In studies 3 and 4 we used an anthropometric formula (Nadler formula) to estimate the 
plasma volume for calculation of the absolute synthesis rates.   
In study 4 the relatively low number of subjects did not allow a description of synthesis rates 
trends in patients undergoing extended hemihepatectomy.  












7 CONCLUSIONS  
Our studies 1, 2, and 4 showed that thromboelastometry can provide important information to 
the clinician regarding the coagulation balance in liver insufficiency.  
Study 1 demonstrated that in a heterogeneous cohort such as the patients scheduled for liver 
transplantation, the thromboelastographic parameters did not have a direct relationship to the 
stage of the liver disease. Our study 1 found no arguments for thromboelastometry to be used 
as a prognostic tool in chronic liver disease. However, our study 1 showed that 
thromboelastometry can assess the balance of coagulation in liver cirrhosis if the definition of 
unbalanced coagulation accepts at least one thromboelastometric parameter to be outside the 
normal range.  
Study 2 contributed to a better understanding of the coagulation system postoperatively after 
major liver resections. We demonstrated, using thromboelastometry, that the hemostasis is 
rebalanced postoperatively in these patients and that standard coagulation tests could mislead 
the clinical judgment indicating a bleeding risk. Accordingly, decisions to treat coagulation 
aberrations should be taken in corroboration with a viscoelastic test. Study 2 gave support to 
the idea of routine thrombosis prophylaxis in patients undergoing liver resections and 
demonstrated that signs of hypercoagulability may appear on thromboelastometry which 
could signal the risk for venous thromboembolism in these patients.  
Study 2 indicated also that the size of the remnant liver following, hemi- vs. extended 
hemihepatectmy, is a factor that can affect the postoperative plasma fibrinogen concentration 
trends. 
Our studies 3 and 4 added knowledge in the domain of de novo synthesis of fibrinogen and 
albumin in healthy subjects and following major abdominal surgery,  
Study 3, a methodological study, established the appropriate time intervals for repeated 
measurements in longitudinal studies exploring de novo synthesis of fibrinogen and albumin 
with maintained precision and accuracy.  
Our study 4, guided by the methodology described in study 3, demonstrated that following 
hemihepatectomy the synthesis of fibrinogen and albumin were well preserved and had the 
capacity to increase over the preoperative values.  Although of lower amplitude following 
hepatectomy, the synthesis rates of fibrinogen were not different from a comparable operation 
without loss of liver tissue (i.e. pancreatectomy). Hence it was discovered the extraordinary 
potentiality of the liver to increase the fibrinogen synthesis postoperatively. It was also 
revealed that the fibrinogen plasma concentrations postoperatively in major abdominal 
surgery, e.g. pancreatectomy or hemihepatectomy, were not solely dependent on fibrinogen 
synthesis but also on utilization.  
Our study 4 demonstrated also that the synthesis of fibrinogen was sharply modulated which 
made possible prevention of substantial abnormalities of plasma fibrinogen concentration. 
This contributed to balanced postoperative coagulation, according to thromboelastometry, 
both following surgical interventions without liver implication or with loss of liver mass. It 
was also demonstrated that an overshot of fibrinogen concentration on postoperative days 3-5 






8 RESEARCH PERSPECTIVES 
Directions for further research nave been opened by our studies as follows: 
Study 1  
To elucidate the correlation between MCF- FIBTEM and Child-Pugh score, a study can be 
designed to explore the relation between MCF-FIBTEM and fibrinogen in advanced stages of 
liver disease. The involvement of fibrin structure modifications might be searched in 
collaboration with centers with experience in dysfibrinogenemia research.  
As a part of the completion of the validation for ROTEM®, studies to determine the 
sensitivity of ROTEM® to hypercoagulability in liver failure are required.  
Establishing the ROTEM® reference range for the population with chronic liver disease is 
possible. This is done for TEG®  at least in one transplantation centre [251]. 
A study to clarify the correlation between platelets count and MCF-FIBTEM in liver cirrhosis 
which was revealed in a post hoc analysis of data from study 1. 
Study 2 
We presume that after large liver resections the trend of the postoperative fibrinogen plasma 
concentration and MCF-FIBTEM, particularly the sharpness of the rebound, could be risk 
markers both for liver insufficiency and for hypercoagulability in these patients. Prospective 
studies to test this hypothesis can be designed. If it is proved to be true, it would add value to 
the prediction of serious risks. 
Study 3 
Research on the possibility to make protein synthesis determinations during the period 
between 5-48 hours after the first determination. 
Develop methodologies to determine the synthesis of coagulation factors with much lower 
plasma concentrations than fibrinogen. Modern mass-spectrometry systems make it possible. 
Study 4 
A study focused on patients with extended liver resections to determine the critical remnant 
liver mass/volume for insufficient fibrinogen and albumin synthesis and the markers of risk. 
In parallel patients undergoing PVE with two-stage hemihepatectomy should be explored to 
determine the relation between the volume of the remnant liver and its synthetic function.  
Studies focused on the postoperative rate of increase of plasma fibrinogen may give 
predictability of the postoperative levels. 
Studies exploring the fibrinogen synthesis intraoperatively and early after the operation 
(major abdominal surgery involving liver and pancreas) may add valuable knowledge.  
Eventually, studies regarding the synthesis of coagulation factors in major liver surgery may 
clarify the mechanisms underlying their plasma concentrations. 
Study 4 reopen the issue of hypercoagulability following large hepatectomies. This issue is 
not settled jet. 
The most exciting perspective opened by study 4 is, we believe, the incitement in deciphering 
the mechanisms of control and modulation of fibrinogen synthesis. Here is a complete lack of 
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knowledge. Studies can be made in animal models to see if induced variations in fibrinogen 
plasma concentrations alter the fibrinogen synthesis. Studies in humans are also possible to 
design. 
Studies regarding fibrinogen and albumin synthesis in chronic liver disease, especially in end-
stage liver disease, can solve the dilemma of how deficiencies in synthesis affect plasma 
concentrations of these two proteins. 
Studies regarding fibrinogen extravasation could be difficult to design but not impossible. 




























9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Vid leversvikt har levern nedsatt förmåga att syntetisera essentiella ämnen för en 
välfungerande metabolism samt att rensa bort metaboliska slutprodukter som inte längre 
behövs. Leversvikt finns i olika stadier, till följd av leversjukdomens utveckling. I allvarliga 
fall den är den enda behandlingen som kan rädda patienten med avancerad leversvikt en 
levertransplantation. Leverdysfunktion inträffar även postoperativt hos de patienter som 
genomgår stor leverkirurgi, där en stor del av levern tas bort. Koagulationsrubbningar 
ackompanjerar alla stadier av leversvikt, både tidigt och sent i förloppet. Orsaken till 
koagulationsrubbningarna vid leversvikt är komplexa och beror i stort sett på att de flesta 
koagulationsfaktorerna produceras i levern. Vi vet sedan tidigare att koagulationen vid stabil 
kronisk leversvikt blir re-balancerad genom mekanismer som uppstår för att kompensera den 
brist på koagulationsfaktorer och trombocyter som karakteriserar dessa patienter. Men vid 
svår dekompensation kan denna fragila balans upphöra. Patienter med leversvikt kan ha lätt 
för att blöda men samtidigt ha en större risk att bilda proppar. 
För att bedöma koagulationsrubbningar tas vanliga koagulationsprover som kan avslöja 
punktuella förändringar i koagulationssystemet men, vid komplexa förändringar, dessa inte 
kan bedöma koagulationens funktionalitet som helhet. Tromboelastometri (ROTEM®) är en 
helblodsanalys där koagelbildning, koagelstyrka och koagelupplösning mäts i samma prov 
vilket ger en global syn över blodets levringsförmåga. På det sättet kan tromboelastometri ge 
upplysning om huruvida koagulationssystemet är balanserat eller inte. Det finns också 
rapporter om att tromboelastometri skulle kunna användas för att bedöma prognosen vid 
kronisk leversvikt. 
Syftet med studierna 1 och 2 var att karakterisera patienter med leversvikt genom att använda 
tromboelastometri. I studie 1 karakteriserades koagulationen hos patienter med kronisk 
leverinsufficiens med indikation för levertransplantation. Vi använde ROTEM® och vanliga 
koagulationsprover. Ett huvudsyfte med den här studien var att undersöka huruvida 
tromboelastometri kan skilja på graden av leversvikt. Vi gjorde korrelationer mellan 
laboratoriedata och alvaret hos leversjukdomen enligt de två vanliga prognosverktyg Child 
Pugh och Model for End-stage Liver Disease (MELD). Slutsatsen var att vi inte kunde hitta 
någon användning av tromboelastometri för att värdera prognosen av den stabila kroniska 
leversjukdomen med indikation för levertransplantation. 
Studie 2 var en deskriptiv pilotstudie med syftet att beskriva det temporala mönstret för 
koagulationsstatus hos patienter som genomgick större leverresektioner. Patienterna 
studerades perioperativt genom att använda en bredare koagulationstestning, inklusive 
ROTEM®. Parallellt registrerades blödning och trombotiska komplikationer. Studies 
huvudslutsats var att ROTEM® visade att patienterna hade en re-balanserad 
koagulationsstatus postoperativt trots avvikande svar på rutinmässiga koagulationsprover. Vi 
observerade även att de postoperativa  fibrinogenivåerna i plasma skiljde sig åt beroende på 
resektionens storlek.  
Ur resultaten i studie 2 framkom hypotesen att en bristande synthesförmåga på grund av 
förlust av levermassa kunde vara en faktor som påverkar fibrinogenets plasma koncentration. 
För att utforska denna hypotes behövde vi kvantitativt kunna mäta de novo syntesen av 
fibrinogen (och albumin) hos dessa patienter. För detta ändamål validerade vi i studie 3 den  
tracer metodiken med användnig av stabila isotoper, som vanligtvis används, för att 
möjligtgöra repetitiva mätningar i longitudinella studier. 
I studie 4 användes metodiken som utvecklades i studie 3 för att undersöka 
fibrinogensyntesen i samband med leverkirurgi. Vi kunde då konstatera att 
fibrinogensyntesen ökade kraftigt den första  postoperativa dagen. Resterande lever efter 
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leverresektion (hepatectomier) hade god förmåga att öka fibrinogensyntesen över de 
preoperativa nivåerna och det fanns ingen skillnad jämfört med en kontoll grupp av patienter 
som genomgick bukspottkörteloperation (pankreatektomier) utan förlust av levervävnad. 
Plasma fibrinogen koncentrationen speglar alltså inte bara syntesförmågan av fibrinogen, utan 
även förbrukningen av fibrinogen. Parallellt undersökte vi även syntesförmågan av albumin, 
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12 ERRATA TO PUBLISHED PAPERS 
 
 
In study 1 on p.3: “Thrombelastometry and child pugh score” should have appeared as 
“Thrombelastometry and Child-Pugh score.” 
 
In study 3, in the legends of Figure 1 and 2 (on p. 5): “Wilcoxon’s t-test for paired 
observations” should have appeared as: “Wilcoxon signed-rank test for paired observations” 

